ZA200300366B - Enhancement of the action of anti-infective agents. - Google Patents
Enhancement of the action of anti-infective agents. Download PDFInfo
- Publication number
- ZA200300366B ZA200300366B ZA200300366A ZA200300366A ZA200300366B ZA 200300366 B ZA200300366 B ZA 200300366B ZA 200300366 A ZA200300366 A ZA 200300366A ZA 200300366 A ZA200300366 A ZA 200300366A ZA 200300366 B ZA200300366 B ZA 200300366B
- Authority
- ZA
- South Africa
- Prior art keywords
- acid
- infections
- agents
- pneumonia
- bacteremia
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title claims description 55
- 229960005475 antiinfective agent Drugs 0.000 title claims description 47
- 230000009471 action Effects 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims description 97
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 89
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 87
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 82
- 229960001225 rifampicin Drugs 0.000 claims description 74
- 238000009472 formulation Methods 0.000 claims description 73
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 56
- 238000002360 preparation method Methods 0.000 claims description 51
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 48
- 239000001272 nitrous oxide Substances 0.000 claims description 43
- 229960005206 pyrazinamide Drugs 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 35
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 29
- 229960000285 ethambutol Drugs 0.000 claims description 28
- 229960002555 zidovudine Drugs 0.000 claims description 28
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 26
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 23
- 229960003085 meticillin Drugs 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 22
- -1 glycerol-polyethylene glycol esters Chemical class 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- 229930195729 fatty acid Natural products 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- 229940056360 penicillin g Drugs 0.000 claims description 15
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims description 15
- 229960003656 ricinoleic acid Drugs 0.000 claims description 15
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims description 15
- 229940088710 antibiotic agent Drugs 0.000 claims description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 14
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 13
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 13
- 229960003942 amphotericin b Drugs 0.000 claims description 13
- 239000003429 antifungal agent Substances 0.000 claims description 13
- 229960003405 ciprofloxacin Drugs 0.000 claims description 13
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 12
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 12
- 229940121375 antifungal agent Drugs 0.000 claims description 12
- 239000011280 coal tar Substances 0.000 claims description 12
- 229960002509 miconazole Drugs 0.000 claims description 12
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 11
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 11
- 229960000723 ampicillin Drugs 0.000 claims description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 229960002182 imipenem Drugs 0.000 claims description 11
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 11
- 229960003350 isoniazid Drugs 0.000 claims description 11
- 229960004130 itraconazole Drugs 0.000 claims description 11
- 230000002685 pulmonary effect Effects 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 229930182566 Gentamicin Natural products 0.000 claims description 10
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 10
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 10
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 10
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 10
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 10
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 9
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229960004150 aciclovir Drugs 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 229960003644 aztreonam Drugs 0.000 claims description 9
- 229960000484 ceftazidime Drugs 0.000 claims description 9
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 9
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 9
- 229960002733 gamolenic acid Drugs 0.000 claims description 9
- 229960002518 gentamicin Drugs 0.000 claims description 9
- 229960002292 piperacillin Drugs 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 8
- 239000004098 Tetracycline Substances 0.000 claims description 8
- 229940124339 anthelmintic agent Drugs 0.000 claims description 8
- 239000000921 anthelmintic agent Substances 0.000 claims description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 8
- 229960003276 erythromycin Drugs 0.000 claims description 8
- 229960004125 ketoconazole Drugs 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 235000019364 tetracycline Nutrition 0.000 claims description 8
- 150000003522 tetracyclines Chemical class 0.000 claims description 8
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 108010059993 Vancomycin Proteins 0.000 claims description 7
- 239000000739 antihistaminic agent Substances 0.000 claims description 7
- 235000021342 arachidonic acid Nutrition 0.000 claims description 7
- 229940114079 arachidonic acid Drugs 0.000 claims description 7
- 229960004022 clotrimazole Drugs 0.000 claims description 7
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 229960004884 fluconazole Drugs 0.000 claims description 7
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 229960005322 streptomycin Drugs 0.000 claims description 7
- 229960002180 tetracycline Drugs 0.000 claims description 7
- 229930101283 tetracycline Natural products 0.000 claims description 7
- 230000001549 tubercolostatic effect Effects 0.000 claims description 7
- 229960003165 vancomycin Drugs 0.000 claims description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 7
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 6
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 6
- 230000001178 anti-ectoparasitic effect Effects 0.000 claims description 6
- 230000002924 anti-infective effect Effects 0.000 claims description 6
- 229940125715 antihistaminic agent Drugs 0.000 claims description 6
- 229960003324 clavulanic acid Drugs 0.000 claims description 6
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 6
- 229940047766 co-trimoxazole Drugs 0.000 claims description 6
- 229960004413 flucytosine Drugs 0.000 claims description 6
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229960004488 linolenic acid Drugs 0.000 claims description 6
- 235000021313 oleic acid Nutrition 0.000 claims description 6
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 5
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 5
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 5
- 108010001478 Bacitracin Proteins 0.000 claims description 5
- 108010015899 Glycopeptides Proteins 0.000 claims description 5
- 102000002068 Glycopeptides Human genes 0.000 claims description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 5
- 108010093965 Polymyxin B Proteins 0.000 claims description 5
- 229960005091 chloramphenicol Drugs 0.000 claims description 5
- 229960003722 doxycycline Drugs 0.000 claims description 5
- 229960003913 econazole Drugs 0.000 claims description 5
- 235000004626 essential fatty acids Nutrition 0.000 claims description 5
- 229960000988 nystatin Drugs 0.000 claims description 5
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 229960002969 oleic acid Drugs 0.000 claims description 5
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 150000003456 sulfonamides Chemical class 0.000 claims description 5
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 4
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 4
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 4
- 229960004821 amikacin Drugs 0.000 claims description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
- 230000002558 anti-leprotic effect Effects 0.000 claims description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 4
- 229960002588 cefradine Drugs 0.000 claims description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 4
- 229960002626 clarithromycin Drugs 0.000 claims description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 4
- 230000002070 germicidal effect Effects 0.000 claims description 4
- 239000000938 histamine H1 antagonist Substances 0.000 claims description 4
- 150000002460 imidazoles Chemical class 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001699 ofloxacin Drugs 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 150000007660 quinolones Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 229960002722 terbinafine Drugs 0.000 claims description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 4
- 229960000580 terconazole Drugs 0.000 claims description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001082 trimethoprim Drugs 0.000 claims description 4
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 3
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 3
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 3
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 claims description 3
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 3
- 229930195708 Penicillin V Natural products 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000003904 antiprotozoal agent Substances 0.000 claims description 3
- 229940124522 antiretrovirals Drugs 0.000 claims description 3
- 239000003903 antiretrovirus agent Substances 0.000 claims description 3
- 229960004099 azithromycin Drugs 0.000 claims description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 3
- 229960003071 bacitracin Drugs 0.000 claims description 3
- 229930184125 bacitracin Natural products 0.000 claims description 3
- 229960005074 butoconazole Drugs 0.000 claims description 3
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002682 cefoxitin Drugs 0.000 claims description 3
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims description 3
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 3
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 3
- 229960004475 chlortetracycline Drugs 0.000 claims description 3
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 3
- 235000019365 chlortetracycline Nutrition 0.000 claims description 3
- 229960003749 ciclopirox Drugs 0.000 claims description 3
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004287 clofazimine Drugs 0.000 claims description 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 3
- 229960003326 cloxacillin Drugs 0.000 claims description 3
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229960005102 foscarnet Drugs 0.000 claims description 3
- 229960002963 ganciclovir Drugs 0.000 claims description 3
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 3
- 229960002867 griseofulvin Drugs 0.000 claims description 3
- 229960001906 haloprogin Drugs 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004716 idoxuridine Drugs 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 3
- 229940041033 macrolides Drugs 0.000 claims description 3
- 229960004313 naftifine Drugs 0.000 claims description 3
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 3
- 229960001180 norfloxacin Drugs 0.000 claims description 3
- 229940056367 penicillin v Drugs 0.000 claims description 3
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 3
- 239000010773 plant oil Substances 0.000 claims description 3
- 229920000024 polymyxin B Polymers 0.000 claims description 3
- 229960005266 polymyxin b Drugs 0.000 claims description 3
- 229960005256 sulbactam Drugs 0.000 claims description 3
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 3
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004214 tioconazole Drugs 0.000 claims description 3
- 229960000707 tobramycin Drugs 0.000 claims description 3
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960003636 vidarabine Drugs 0.000 claims description 3
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 claims description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims description 2
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 claims description 2
- RUXPNBWPIRDVTH-UHFFFAOYSA-N Amifloxacin Chemical compound C1=C2N(NC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 RUXPNBWPIRDVTH-UHFFFAOYSA-N 0.000 claims description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims description 2
- 108010065839 Capreomycin Proteins 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims description 2
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 claims description 2
- 239000004099 Chlortetracycline Substances 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 2
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004100 Oxytetracycline Substances 0.000 claims description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 2
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 claims description 2
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 claims description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
- 108010053950 Teicoplanin Proteins 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 229950009484 amifloxacin Drugs 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 230000000507 anthelmentic effect Effects 0.000 claims description 2
- XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical compound C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 claims description 2
- 229950001979 apalcillin Drugs 0.000 claims description 2
- 229960002278 azidamfenicol Drugs 0.000 claims description 2
- SGRUZFCHLOFYHZ-MWLCHTKSSA-N azidamfenicol Chemical compound [N-]=[N+]=NCC(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 SGRUZFCHLOFYHZ-MWLCHTKSSA-N 0.000 claims description 2
- 229960003623 azlocillin Drugs 0.000 claims description 2
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 claims description 2
- 229960002699 bacampicillin Drugs 0.000 claims description 2
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 claims description 2
- 229960004602 capreomycin Drugs 0.000 claims description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 2
- 229960002543 carfecillin Drugs 0.000 claims description 2
- NZDASSHFKWDBBU-KVMCETHSSA-N carfecillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)C(=O)OC1=CC=CC=C1 NZDASSHFKWDBBU-KVMCETHSSA-N 0.000 claims description 2
- 229960000717 carindacillin Drugs 0.000 claims description 2
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- 229960004841 cefadroxil Drugs 0.000 claims description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 2
- 229950006669 cefalexin pivoxil Drugs 0.000 claims description 2
- DIGADQKVPFDJSI-SPYBWZPUSA-N cefalexin pivoxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DIGADQKVPFDJSI-SPYBWZPUSA-N 0.000 claims description 2
- 229960003866 cefaloridine Drugs 0.000 claims description 2
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 2
- 229960003012 cefamandole Drugs 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960003719 cefdinir Drugs 0.000 claims description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 2
- 229950000726 cefetamet pivoxil Drugs 0.000 claims description 2
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 claims description 2
- 229960002129 cefixime Drugs 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229960003791 cefmenoxime Drugs 0.000 claims description 2
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims description 2
- 229960001958 cefodizime Drugs 0.000 claims description 2
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 claims description 2
- 229960004489 cefonicid Drugs 0.000 claims description 2
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 claims description 2
- 229960004682 cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960004292 ceforanide Drugs 0.000 claims description 2
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 claims description 2
- 229960005495 cefotetan Drugs 0.000 claims description 2
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 2
- 229960001242 cefotiam Drugs 0.000 claims description 2
- 229960005446 cefpiramide Drugs 0.000 claims description 2
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 claims description 2
- 229960002580 cefprozil Drugs 0.000 claims description 2
- 229960003202 cefsulodin Drugs 0.000 claims description 2
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 claims description 2
- 229960004086 ceftibuten Drugs 0.000 claims description 2
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 claims description 2
- 229960001991 ceftizoxime Drugs 0.000 claims description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229960002620 cefuroxime axetil Drugs 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- NPGNOVNWUSPMDP-UTEPHESZSA-N chembl1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 claims description 2
- 229960004375 ciclopirox olamine Drugs 0.000 claims description 2
- 229960004621 cinoxacin Drugs 0.000 claims description 2
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- 229960000860 dapsone Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229960002398 demeclocycline Drugs 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- 229960002656 didanosine Drugs 0.000 claims description 2
- 229960002549 enoxacin Drugs 0.000 claims description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000740 enrofloxacin Drugs 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002001 ethionamide Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003306 fleroxacin Drugs 0.000 claims description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- 229960003884 hetacillin Drugs 0.000 claims description 2
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 claims description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 2
- 229960001627 lamivudine Drugs 0.000 claims description 2
- 229960000433 latamoxef Drugs 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960002422 lomefloxacin Drugs 0.000 claims description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001977 loracarbef Drugs 0.000 claims description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 claims description 2
- 229960002260 meropenem Drugs 0.000 claims description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 2
- 229940042016 methacycline Drugs 0.000 claims description 2
- 229960004011 methenamine Drugs 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 229960003808 nadifloxacin Drugs 0.000 claims description 2
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- 229960000210 nalidixic acid Drugs 0.000 claims description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 229960000564 nitrofurantoin Drugs 0.000 claims description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 229960000321 oxolinic acid Drugs 0.000 claims description 2
- 229960000625 oxytetracycline Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 235000019366 oxytetracycline Nutrition 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004236 pefloxacin Drugs 0.000 claims description 2
- 229960001179 penciclovir Drugs 0.000 claims description 2
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960001732 pipemidic acid Drugs 0.000 claims description 2
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004444 piromidic acid Drugs 0.000 claims description 2
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003342 pivampicillin Drugs 0.000 claims description 2
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 claims description 2
- 229960004212 pivmecillinam Drugs 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229950003551 ramoplanin Drugs 0.000 claims description 2
- 108010076689 ramoplanin Proteins 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 229960000885 rifabutin Drugs 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960003889 rosoxacin Drugs 0.000 claims description 2
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005224 roxithromycin Drugs 0.000 claims description 2
- 229960004062 rufloxacin Drugs 0.000 claims description 2
- 229950009279 sorivudine Drugs 0.000 claims description 2
- 229960004954 sparfloxacin Drugs 0.000 claims description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 2
- 229960000268 spectinomycin Drugs 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229960001203 stavudine Drugs 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 claims description 2
- FEPTXVIRMZIGFY-UHFFFAOYSA-N sulfisoxazole diolamine Chemical compound OCCNCCO.CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C FEPTXVIRMZIGFY-UHFFFAOYSA-N 0.000 claims description 2
- 229940032483 sulfisoxazole diolamine Drugs 0.000 claims description 2
- 229960002780 talampicillin Drugs 0.000 claims description 2
- 229960001608 teicoplanin Drugs 0.000 claims description 2
- 229960001114 temocillin Drugs 0.000 claims description 2
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 2
- 229960003053 thiamphenicol Drugs 0.000 claims description 2
- 229960004659 ticarcillin Drugs 0.000 claims description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 2
- 229960004880 tolnaftate Drugs 0.000 claims description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 2
- 229950008187 tosufloxacin Drugs 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- 229940075466 undecylenate Drugs 0.000 claims description 2
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- 229940044959 vaginal cream Drugs 0.000 claims description 2
- 239000000522 vaginal cream Substances 0.000 claims description 2
- 229940098946 vaginal ointment Drugs 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 229960000523 zalcitabine Drugs 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229960002673 sulfacetamide Drugs 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 claims 1
- SKVLYVHULOWXTD-UHFFFAOYSA-N N-succinylsulfathiazole Chemical compound C1=CC(NC(=O)CCC(=O)O)=CC=C1S(=O)(=O)NC1=NC=CS1 SKVLYVHULOWXTD-UHFFFAOYSA-N 0.000 claims 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 1
- 229960003077 cycloserine Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002721 mafenide acetate Drugs 0.000 claims 1
- 229960001106 phthalylsulfathiazole Drugs 0.000 claims 1
- PBMSWVPMRUJMPE-UHFFFAOYSA-N phthalylsulfathiazole Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(S(=O)(=O)\N=C\2SC=CN/2)C=C1 PBMSWVPMRUJMPE-UHFFFAOYSA-N 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 229960005379 succinylsulfathiazole Drugs 0.000 claims 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004306 sulfadiazine Drugs 0.000 claims 1
- 229960004673 sulfadoxine Drugs 0.000 claims 1
- 229960000654 sulfafurazole Drugs 0.000 claims 1
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 claims 1
- 229960004257 sulfaguanidine Drugs 0.000 claims 1
- 229960000468 sulfalene Drugs 0.000 claims 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 claims 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 claims 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 claims 1
- 229960004936 sulfamethoxypyridazine Drugs 0.000 claims 1
- 229960002229 sulfametoxydiazine Drugs 0.000 claims 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 claims 1
- 229960002211 sulfapyridine Drugs 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 claims 1
- 229960003865 tazobactam Drugs 0.000 claims 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 161
- 208000031729 Bacteremia Diseases 0.000 description 148
- 206010035664 Pneumonia Diseases 0.000 description 148
- 208000019206 urinary tract infection Diseases 0.000 description 107
- 206010014665 endocarditis Diseases 0.000 description 83
- 201000009890 sinusitis Diseases 0.000 description 72
- 241000588747 Klebsiella pneumoniae Species 0.000 description 70
- 239000003814 drug Substances 0.000 description 65
- 229930182555 Penicillin Natural products 0.000 description 61
- 229940079593 drug Drugs 0.000 description 61
- 229940049954 penicillin Drugs 0.000 description 59
- 201000009906 Meningitis Diseases 0.000 description 54
- 210000001635 urinary tract Anatomy 0.000 description 52
- 238000011282 treatment Methods 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 49
- 206010000269 abscess Diseases 0.000 description 46
- 241000894007 species Species 0.000 description 43
- 206010011409 Cross infection Diseases 0.000 description 41
- 229940126575 aminoglycoside Drugs 0.000 description 41
- 230000000694 effects Effects 0.000 description 41
- 241000588770 Proteus mirabilis Species 0.000 description 36
- 201000008827 tuberculosis Diseases 0.000 description 35
- 206010007882 Cellulitis Diseases 0.000 description 32
- 201000007100 Pharyngitis Diseases 0.000 description 32
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- 208000005141 Otitis Diseases 0.000 description 29
- 206010033078 Otitis media Diseases 0.000 description 29
- 208000019258 ear infection Diseases 0.000 description 29
- 241000193998 Streptococcus pneumoniae Species 0.000 description 26
- 206010003246 arthritis Diseases 0.000 description 26
- 241000588724 Escherichia coli Species 0.000 description 25
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 25
- 208000001388 Opportunistic Infections Diseases 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- 230000012010 growth Effects 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 22
- 241000588655 Moraxella catarrhalis Species 0.000 description 22
- 241000607720 Serratia Species 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 22
- 241000588769 Proteus <enterobacteria> Species 0.000 description 21
- 241000191967 Staphylococcus aureus Species 0.000 description 20
- 241000607447 Yersinia enterocolitica Species 0.000 description 20
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 20
- 229940098232 yersinia enterocolitica Drugs 0.000 description 20
- 206010040047 Sepsis Diseases 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 18
- 206010031252 Osteomyelitis Diseases 0.000 description 18
- 241000194017 Streptococcus Species 0.000 description 18
- 229960003677 chloroquine Drugs 0.000 description 18
- 241000589291 Acinetobacter Species 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 244000045947 parasite Species 0.000 description 17
- 206010010741 Conjunctivitis Diseases 0.000 description 16
- 206010035148 Plague Diseases 0.000 description 16
- 208000025865 Ulcer Diseases 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 230000009885 systemic effect Effects 0.000 description 16
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 241000588914 Enterobacter Species 0.000 description 15
- 201000000297 Erysipelas Diseases 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 206010039587 Scarlet Fever Diseases 0.000 description 15
- 241000193985 Streptococcus agalactiae Species 0.000 description 15
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 15
- 201000003453 lung abscess Diseases 0.000 description 15
- 229960005040 miconazole nitrate Drugs 0.000 description 15
- 206010014568 Empyema Diseases 0.000 description 14
- 241000605986 Fusobacterium nucleatum Species 0.000 description 14
- 206010048461 Genital infection Diseases 0.000 description 14
- 206010041925 Staphylococcal infections Diseases 0.000 description 14
- 241000193996 Streptococcus pyogenes Species 0.000 description 14
- 208000007565 gingivitis Diseases 0.000 description 14
- 206010002515 Animal bite Diseases 0.000 description 13
- 241000186216 Corynebacterium Species 0.000 description 13
- 241000588653 Neisseria Species 0.000 description 13
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 13
- 206010048038 Wound infection Diseases 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241000193738 Bacillus anthracis Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 206010037888 Rash pustular Diseases 0.000 description 12
- 208000002474 Tinea Diseases 0.000 description 12
- 229940065181 bacillus anthracis Drugs 0.000 description 12
- 230000003211 malignant effect Effects 0.000 description 12
- 208000029561 pustule Diseases 0.000 description 12
- 230000035899 viability Effects 0.000 description 12
- 241000233866 Fungi Species 0.000 description 11
- 206010048249 Yersinia infections Diseases 0.000 description 11
- 208000025079 Yersinia infectious disease Diseases 0.000 description 11
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010023332 keratitis Diseases 0.000 description 11
- 241000606768 Haemophilus influenzae Species 0.000 description 10
- 208000007514 Herpes zoster Diseases 0.000 description 10
- 241000607479 Yersinia pestis Species 0.000 description 10
- 208000010217 blepharitis Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 208000005577 Gastroenteritis Diseases 0.000 description 9
- 208000007027 Oral Candidiasis Diseases 0.000 description 9
- 241000606860 Pasteurella Species 0.000 description 9
- 108010087702 Penicillinase Proteins 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 238000011835 investigation Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 229950009506 penicillinase Drugs 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 8
- 241000193468 Clostridium perfringens Species 0.000 description 8
- 201000000628 Gas Gangrene Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 241000589969 Borreliella burgdorferi Species 0.000 description 7
- 208000014260 Fungal keratitis Diseases 0.000 description 7
- 208000016604 Lyme disease Diseases 0.000 description 7
- 241000588650 Neisseria meningitidis Species 0.000 description 7
- 241000607142 Salmonella Species 0.000 description 7
- 201000010618 Tinea cruris Diseases 0.000 description 7
- 208000012873 acute gastroenteritis Diseases 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 7
- 230000001524 infective effect Effects 0.000 description 7
- VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 7
- 229960000198 mezlocillin Drugs 0.000 description 7
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 7
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 7
- 201000004647 tinea pedis Diseases 0.000 description 7
- 241000589874 Campylobacter fetus Species 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 208000004232 Enteritis Diseases 0.000 description 6
- 241000194033 Enterococcus Species 0.000 description 6
- 241000589242 Legionella pneumophila Species 0.000 description 6
- 208000007764 Legionnaires' Disease Diseases 0.000 description 6
- 241000186779 Listeria monocytogenes Species 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 6
- 206010033971 Paratyphoid fever Diseases 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 208000037386 Typhoid Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229940115932 legionella pneumophila Drugs 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 201000008297 typhoid fever Diseases 0.000 description 6
- 208000000143 urethritis Diseases 0.000 description 6
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 5
- 208000004020 Brain Abscess Diseases 0.000 description 5
- 241000589562 Brucella Species 0.000 description 5
- 206010006500 Brucellosis Diseases 0.000 description 5
- 241000589875 Campylobacter jejuni Species 0.000 description 5
- 206010008631 Cholera Diseases 0.000 description 5
- 241000193449 Clostridium tetani Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241000228404 Histoplasma capsulatum Species 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 5
- 241000606856 Pasteurella multocida Species 0.000 description 5
- 229920000153 Povidone-iodine Polymers 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 241001478880 Streptobacillus moniliformis Species 0.000 description 5
- 206010043376 Tetanus Diseases 0.000 description 5
- 208000007712 Tinea Versicolor Diseases 0.000 description 5
- 206010056131 Tinea versicolour Diseases 0.000 description 5
- 241000893966 Trichophyton verrucosum Species 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229940047650 haemophilus influenzae Drugs 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 201000004792 malaria Diseases 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229940051027 pasteurella multocida Drugs 0.000 description 5
- 229960001621 povidone-iodine Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000186041 Actinomyces israelii Species 0.000 description 4
- 206010003757 Atypical pneumonia Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010005913 Body tinea Diseases 0.000 description 4
- 241001136175 Burkholderia pseudomallei Species 0.000 description 4
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 4
- 101100298222 Caenorhabditis elegans pot-1 gene Proteins 0.000 description 4
- 206010007134 Candida infections Diseases 0.000 description 4
- 241001647372 Chlamydia pneumoniae Species 0.000 description 4
- 241000606153 Chlamydia trachomatis Species 0.000 description 4
- 201000007336 Cryptococcosis Diseases 0.000 description 4
- 241000221204 Cryptococcus neoformans Species 0.000 description 4
- 208000007163 Dermatomycoses Diseases 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 206010015146 Erysipeloid Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000589602 Francisella tularensis Species 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000005100 Herpetic Keratitis Diseases 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 241000187678 Nocardia asteroides Species 0.000 description 4
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 4
- 206010038910 Retinitis Diseases 0.000 description 4
- 241000607768 Shigella Species 0.000 description 4
- 241000295644 Staphylococcaceae Species 0.000 description 4
- 241000130764 Tinea Species 0.000 description 4
- 241000287411 Turdidae Species 0.000 description 4
- 241000607626 Vibrio cholerae Species 0.000 description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 4
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000001355 anti-mycobacterial effect Effects 0.000 description 4
- 239000003926 antimycobacterial agent Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 201000003984 candidiasis Diseases 0.000 description 4
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940038705 chlamydia trachomatis Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000005035 cutaneous candidiasis Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 201000004015 melioidosis Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- PQMSFAORUFMASU-UHFFFAOYSA-M sulfacetamide sodium anhydrous Chemical compound [Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 PQMSFAORUFMASU-UHFFFAOYSA-M 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 201000003875 tinea corporis Diseases 0.000 description 4
- 206010044325 trachoma Diseases 0.000 description 4
- 229940118696 vibrio cholerae Drugs 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 241000180135 Borrelia recurrentis Species 0.000 description 3
- 241000195940 Bryophyta Species 0.000 description 3
- 241000722910 Burkholderia mallei Species 0.000 description 3
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 241000223205 Coccidioides immitis Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000589566 Elizabethkingia meningoseptica Species 0.000 description 3
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 description 3
- 201000003641 Glanders Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010037151 Psittacosis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241001149963 Sporothrix schenckii Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 241000589884 Treponema pallidum Species 0.000 description 3
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- 208000034784 Tularaemia Diseases 0.000 description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 206010008323 cervicitis Diseases 0.000 description 3
- 201000004308 chancroid Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 208000001606 epiglottitis Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000010666 keratoconjunctivitis Diseases 0.000 description 3
- 201000009837 laryngotracheitis Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 235000011929 mousse Nutrition 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000009670 mycobacterial growth Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 201000000901 ornithosis Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 208000007865 relapsing fever Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 201000009482 yaws Diseases 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010005098 Blastomycosis Diseases 0.000 description 2
- 208000021721 Brill-Zinsser disease Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- 101100298225 Caenorhabditis elegans pot-2 gene Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241001647378 Chlamydia psittaci Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940123930 Lactamase inhibitor Drugs 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 241000293007 Moraxella canis Species 0.000 description 2
- 206010028282 Murine typhus Diseases 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010037688 Q fever Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010038017 Recrudescent typhus Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000606723 Rickettsia akari Species 0.000 description 2
- 201000004282 Rickettsialpox Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 241000202921 Ureaplasma urealyticum Species 0.000 description 2
- 208000028207 Weil disease Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 229940034014 antimycobacterial agent Drugs 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 2
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 238000009506 drug dissolution testing Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010014801 endophthalmitis Diseases 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 244000000056 intracellular parasite Species 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- HCRKCZRJWPKOAR-SNVBAGLBSA-N (4s)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide Chemical compound CCN[C@@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-SNVBAGLBSA-N 0.000 description 1
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 1
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 238000007303 Carboni reaction Methods 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014199 Eczema infected Diseases 0.000 description 1
- 206010014671 Endocarditis enterococcal Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000003809 Herpes Zoster Ophthalmicus Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010034236 Pelvic abscess Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000006588 Pleural Empyema Diseases 0.000 description 1
- 206010035673 Pneumonia chlamydial Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 206010044756 Tuberculous infections Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960005364 bacitracin zinc Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229940057194 bleph-10 Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100001018 bone marrow damage Toxicity 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940087451 cytovene Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- PRUSTPADOGZAML-LMXGZOGMSA-N erythromycin E Chemical compound C([C@H]1C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@@H](C)[C@@H]1O1)(C)O)CC)O[C@]21C[C@@](C)(OC)[C@@H](O)[C@H](C)O2 PRUSTPADOGZAML-LMXGZOGMSA-N 0.000 description 1
- PRUSTPADOGZAML-UHFFFAOYSA-N erythromycin E Natural products O1C2C(C)C(OC3C(C(CC(C)O3)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C2COC21CC(C)(OC)C(O)C(C)O2 PRUSTPADOGZAML-UHFFFAOYSA-N 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229940108452 foscavir Drugs 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229940072360 garamycin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- YMWQIYMUNZBOOV-AQQDCCNYSA-N hms2094o05 Chemical compound CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@@H](C3=CC(O)=CC(OC4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(O)=O)=O)Cl)=C(OC=2C(=CC(CC(C(N4)=O)NC(=O)[C@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 YMWQIYMUNZBOOV-AQQDCCNYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 229940064238 ilotycin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229940091015 isopto cetamide Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000865 membrane-inlet mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000013842 nitrous oxide Nutrition 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 201000004284 spotted fever Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940035721 sulf-10 Drugs 0.000 description 1
- 229960000551 sulfacetamide sodium Drugs 0.000 description 1
- 229950006904 sulfisoxazole acetyl Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229940035275 tobrex Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000000083 urinary anti-infective agent Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS bd FIELD OF THE INVENTION
This invention relates to pharmaceutical preparations (which expression is herein intended to include veterinary preparations) for use in combating infective organisms afflicting the animal body (which expression is herein intended to include the human body).
In EP 93912877.3 and US patent 5,633,284 and their equivalents the applicant disclosed that dermatological or topical compositions comprising the combination of nitrous oxide [N20] and at least one fatty acid, or lower alkyl ester thereof in a dermatologically acceptable carrier medium are useful in the treatment of a variety of skin, muscle and joint disorders. It also disclosed therein that such combinations may beneficially also include additional active ingredients.
Known anti-bacterial, anti-viral or anti-fungal agents were not amongst the active ingredients specifically mentioned in the patents but mention was made therein that coal tar solution (also known as Liquor Picis
Carbonis) may be used as a supplementary active ingredient and that the resultant preparation is suitable for use in the treatment of, inter alia fever blisters, herpes simplex, shingles and chicken pox. While all of these conditions are caused by viral infections, the disclosures in these patents do not refer to that fact.
It is also disclosed in these patents that, in addition to the coal tar solution the composition may also contain an H1l-antagonist antihistamine (e.g. diphenhydramine hydrochloride) and may in that form be used in } the treatment of atopic and allergic conditions manifesting in skin irritations such as eczema, dermatitis and ringworm. The latter of these conditions is caused by a fungal infection. Again the disclosures in issue do not refer specifically to that fact. » It further disclosed an alternative composition in which the coal tar solution formulation is further provided with collagen and lanolin and this ' formulation was found to be useful in the treatment of persons suffering from acne vulgaris. Bacteria are involved in the condition but no mention was made of such involvement in those patents.
Since coal tar solution is in itself not known to be an anti-viral, anti-fungal ; or antibacterial agent, and has merely been mentioned as being weakly antiseptic, the aforementioned disclosures would not have been “ understood as suggesting that the nitrous oxide and fatty acid combination has any beneficial effect on the anti-viral or anti-fungal or anti-bacterial activity of any recognised anti-viral or anti-fungal or anti- bacterial agent or to have disclosed that such properties are displayed by coal tar solution. As will appear below the enhancement of the anti- bacterial, anti-fungal or anti-viral properties of known agents lie at the very heart of this invention.
Within the context of the disclosure in the abovementioned patent family the notional addressee most likely would, as did the inventor, have understood the role of the coal tar solution to sooth the itching and to assist in the repairing and healing of the skin which was damaged as a result of the infections/conditions in issue.
In W097/17978 and US Patent 6,221,377 and in corresponding patents and pending patent applications in other jurisdictions the present applicant disclosed that the action of analgesic, anti-inflammatory and anti-pyretic drugs may be enhanced by administering such drugs in conjunction with a medium which comprises nitrous oxide and at least one long chain fatty acid selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma linolenic acid, arachidonic acid, and any of the C; to Cs alkyl esters of such long chain fatty acids, mixtures of such acids and mixtures of such esters. The medium may comprise the mixture known as Vitamin F Ethyl Ester and may optionally further comprise eicosapentaenoic acid [C20: 5w3] and decosahexaenoic acid [C22: 6w3].
EE It has now surprisingly been found that the aforesaid medium and media related thereto has the ability remarkably to enhance the action of known anti-infective agents. The expression “anti-infective agents” as used herein is intended to have its extended meaning and to include the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but to exclude coal tar solution and H1l-antagonist antihistamines. .
R
The exclusion of coal tar solution and H1l-antagonist antihistamines from 40 the ambit of the present invention is introduced without thereby ! conceding that the aforementioned patents and applications contain any disclosure of any anti-infective agent properties of such excluded compounds, or that such properties are obvious in the light of the : disclosures in such patents or applications. Such inferences are specifically denied. The exclusion is introduced simply to avoid what is , anticipated to be a potential obstacle to the grant of a patent in respect of an insignificant part of potential subject matter which part in itself is not considered worth contesting during examination as it might unduly delay the implementation in practice of the significant features of the present invention. It is expected that the remaining bulk of the subject matter of the present invention will greatly contribute to the accessibility of medicines for the treatment of a large range of infections, including secondary infections in HIV-compromised patients, at significantly reduced costs.
The expressions “anthelmintic agents” and “anti-ectoparasitic” agents are further intended to cover both agents which serve to destroy and those which serve to inhibit the proliferation of helminths or ecto-parasites.
Those expressions are hence also intended to be understood in the wider sense of these terms. The expression “antimicrobial agents” is similarly intended to be understood in the wider sense of that word and hence to have the meaning ascribed thereto in The McGraw-Hill Dictionary of
Scientific and Technical Terms 2" Ed 1978, namely all chemical compounds that either destroy or inhibit the growth of microscopic and sub microscopic organisms. This term is further specifically intended to include all the compounds falling within the Pharmacological Classification 20 set out as part of Regulation 5(1) of the General Regulations made in terms of the South African Medicines and Related Substances Control Act,
Act 101 of 1965, as well as the active ingredients of all products falling within class 18 of the pharmacological classification employed in the
Monthly Index of Medical Specialities ("MIMS") published by Times Media in South Africa. It is thus intended to include: the anti-bacterial agents (including both antibiotics and substances other than antibiotics such as the sulfonamides, the erythromycins and other macrolides, the aminoglycocides, the tetracyclines, the chloramphenicols and the quinolones); the anti-fungal agents; . the anti-viral agents (including anti-retroviral agents); the anti-protozoal agents; the tuberculostatics; ’ 40 the anti-leprotics; the germicides; and the spirochaeticides.
The surprising finding of enhancement of action of the anti-infective agents referred to above is made against the background of the fact that . there appears to be no earlier suggestion in the literature to the effect that either nitrous oxide or the long chain fatty acids used in the formulation referred to above, and hence also not the combination of these, has any effect whatsoever on the sensitivity of any micro-organism to any anti-infective agent.
The present invention is specifically, though not exclusively aimed at the enhancement of the action of anti-mycobacterial agents, and particularly those used in the treatment of patients infected with Mycobacterium tuberculosis (M.Tb.). This organism is one of the most significant human pathogens. It is responsible for an estimated seven million new cases of tuberculosis annually, and an estimated three million deaths worldwide.
Of particular concern is the emergence of tuberculosis (TB) as an increasing cause of morbidity and mortality among persons compromised by human immune-deficiency virus (HIV) infection.
Although the prevalence of tuberculosis in developed countries declined in the first few decades of the 1900's, this trend has reversed and an increased incidence of tuberculosis has been reported in many countries.
Africa alone is estimated to have approximately 170 million TB patients.
In South Africa the incidence of tuberculosis is also rising and is at different levels in different population groups. The chapter on
Tuberculosis in the 1999 edition of South African Health Review (available at http://www.hst.org.za/sahr/) opens with the shocking statement that: "Despite the availability of effective and affordable treatment, the number of South Africans dying from tuberculosis continues to increase”. It is echoed by the summary of the startling overview in which it is recorded that "A reported incidence of 254 cases per 100 000 for the period 1996 - 1998 combined with low cure rates, indicate that the epidemic is still out of control. Rising levels of HIV infection and multi-drug resistant TB (MDR TB) represent additional threats to TB control efforts.” The number of reported cases of pulmonary TB (PTB) is reported in the Review to have risen from 90628 . to 110016 new reported cases per year over the period 1996 to 1998, the N estimated report rate having increased over the same period from 64% to \ 40 71%. Some of the provinces in South Africa contributed significantly to the national average TB incidence figure of 254 referred to above. The quoted Review reflects the figure for Eastern Cape as 388, for the
Northern Cape as 360, the Free State as 338 and the Western Cape as : about 500 per 100000, almost double the national average. It has been reported elsewhere that the highest incidence of TB in the country is
A found in certain communities in the Western Cape where the estimated 5 incidence is as high as 1400 per 100000.
Re-infection of patients is an ever-increasing problem and has been shown to be a function of reactivation of TB in patients not completing their therapy. It is also often associated with the appearance of drug resistant M.Tb. in the patient. The exact mechanism whereby drug resistance develops in mycobacteria is not yet fully understood, but the economic consequences thereof are a reality. The occurrence of drug resistant strains of M.Tb., generally known as multi-drug resistant
Tuberculosis ("MDR TB") is also referred to in the aforementioned South
African Health Review 1999. It states: “Accurate figures for MDR TB are currently not available but surveys in three provinces (Western Cape,
Mpumalanga and Gauteng) indicate a rate of 1% in new MDR TB cases, 4% in retreatment cases. This translates to at least 2 000 newly active cases of MDR TB in South Africa each year. MDR TB is extremely expensive to treat - R25 000 to R30 000 per patient for the drugs alone as opposed to less than R200 for a new patient with ordinary TB. Such patients generally also require to be hospitalised for long periods of time (usually between six and eighteen months), adding significantly to the cost of their treatment”
In an attempt to reduce discontinuance of TB-treatments which has been implicated in reinfections and the development of resistant strains, the practice of directly observed treatment or DOTS has been resorted to, with some, but based on the foregoing quotes, not complete success.
Iron, heavy metals, and excessive alcohol consumption (an inherent feature of some identified high incidence TB communities) generate harmful reactive oxygen species which have been shown to be involved in the auto-oxidation of Rifampicin, an antibiotic anti-mycobacterial agent used in the treatment of tuberculosis, thereby generating more radical ] species. These free radicals have been implicated in the liver toxicity experienced with use of Rifampicin.
These problems associated with TB have led to the investigations 40 associated with the present invention.
It was pointed out in WO97/17978 referred to above that nitrous oxide is a natural gas which is also produced synthetically, and also known by the - trivial name "laughing gas” which has been in use for many years as an inhalation anaesthetic and analgesic, particularly in dentistry. .
It was further stated that nitrous oxide has been reported to have a synergistic or potentiating effect on halothane and other gaseous anaesthetics [See Goodman & Gilman's The Pharmacological Basis of
Therapeutics 8th Ed. 1990 pp. 298-300].
Since such known synergism or potentiation is based on the use of nitrous oxide administered by inhalation, and since the use of nitrous oxide on its own as an anaesthetic and analgesic has likewise been in the form of an inhalation agent, the use of nitrous oxide for all these purposes have been confined to hospitalised patients or, at best, to treatments carried out by medical practitioners in their consulting rooms, or treatments carried out by or under supervision of a nurse in charge of a home-care patient.
Nitrous oxide is known to be soluble in water and it has been reported that at 20°C and 2 atm pressure one litre of the gas dissolves in 1,5 litres of water, see The Merck Index 10th Ed. p. 6499.
Nitrous oxide is also known for its use as a propellant gas, mainly as a substitute for propellant gases such as chlorofluorocarbons, and more particularly to produce a food product mousse such as whipped cream or chocolate mousse or quick-breaking foams for hair treatment preparations. See in this regard U.K. Patent 1033299, U.K. Patent 1105919 and European Patent Application EPA-0123827. None of these prior publications suggests that the nitrous oxide gas plays any other role than a physical one, i.e. to expand on being depressurised and thereby to create a mousse or foam. In fact it is typically regarded as an inert in these applications and useful due to the fact that it is colourless, odourless and tasteless but soluble in water and oils.
There appears to be no suggestion in the literature, other than the applicants own prior patents and patent applications referred to above, that aqueous solutions of nitrous oxide might have any effect on man or . animals. As far as the present applicant knows, it has also never been suggested that nitrous oxide may be used in conjunction with any anti- 40 infective agent to enhance the known action of such agent. ’
It is known in the pharmaceutical field to formulate active ingredients in . so-called liposomal formulations. Unlike the present invention which is based on formulations containing long chain fatty acids and esters thereof the liposomes are based on a clearly distinguishable group of compounds ‘ 5 namely the phospholipids, and generally also contain cholesterol as a stabilising agent and may further contain lisolecitein. These compounds or classes form no part of the present invention and, in case it is necessary to do so, are specifically excluded from the group of long chain fatty acids and derivatives thereof incorporated in the method or formulation of the invention.
It is an object of the present invention to provide a method of enhancing the known action of anti-infective agents and to provide pharmaceutical preparations of such anti-infective agents which preparations have enhanced action compared to the action of known formulations containing the same agents.
These objects stem from the observations made by present applicant in respect of a selection of agents falling within the group of anti-infective agents as herein defined, which can advantageously be formulated with nitrous oxide and an oil based on long chain fatty acids disclosed herein, to elicit a more potent response, for each agent according to its own inherent properties, or to evoke such response more rapidly than it does when used by conventional administration of the agent in issue.
According to the present invention there is provided a method of enhancing the action of an anti-infective agent characterised in that the agent is selected from the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, comprising the step of formulating the agent with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic ’ acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and derivatives thereof : 40 selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. -
According to a further aspect of the present invention there is provided a pharmaceutical preparation comprising an anti-infective agent characterised in that it is selected from the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, which agent is formulated with an administration medium which comprises a solution of nitrous oxide in a pharmaceutically acceptable carrier solvent for the gas and which includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and the derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil, with ethylene oxide.
The administration medium preferably includes the eicosapentaenoic acid [C20: 5w3] and/or decosahexaenoic acid [C22: 6w3] as additional long chain fatty acids to at least one of the other components of the carrier medium defined above.
The reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils with ethylene oxide is preferably produced from castor oil of which the fatty acid content is known to be predominantly composed of ricinoleic acid. This product is known as PEG-n-Hydrogenated
Castor Oil. A range of such products is marketed by BASF under the trade description of Cremophor RH grades. Glycerol-polyethylene glycol ester of ricinoleic acid is also marketed by the same company but under the trade description of Cremophor EL.
The carrier solvent for the nitrous oxide gas may be water or any of the pharmaceutically acceptable alcohols, ethers, oils or polymers such as a polyethylene glycol or the like. The oil may be organic or mineral oil. The . organic oil may be an essential oil based on long chain fatty acids having between 14 and 22 carbon atoms in the fatty acid. The oil may also be of 40 either natural or synthetic origin and, if of natural origin, it may be either i plant oil or animal oil. As plant oils those rich in gamma linolenic acid
[GLA] are preferred and as animal oil dairy cream may be used.
In the preferred form of the invention the solution is an aqueous solution saturated with nitrous oxide. Preferably the water is deionised and purified to be free of microbes.
When the formulation containing the anti-infective agent to be enhanced by means of the nitrous oxide is to be in a liquid (including an encapsulated liquid) presentation for oral administration or in a nasal or bronchial or pulmonary spray or in the form of an injectable formulation, such formulation may incorporate, as part of the administration medium, water or acceptable other liquid into which the nitrous oxide is dissolved and in which the fatty acid or ester thereof is either dissolved or suspended or emulsified along with the anti-infective agent to be enhanced by being formulated therewith.
Likewise, where the anti-infective agent is to be administered to the patient as a topical, buccal or vaginal cream or ointment, or as a suppository, the formulation used in making up such cream, ointment, or suppository may incorporate, along with the anti-infective agent to be enhanced, a quantity of water or other liquid containing, and preferably saturated with, nitrous oxide, the long chain fatty acid or ester thereof and the anti-infective agent formulated therewith, and, further, such additional excipients and carriers as are conventionally used in the pharmaceutical trade in making up such dosage forms.
The carrier solvent for the nitrous oxide gas may thus in an alternative formulation according to the invention be essentially non-aqueous and composed of least one fatty acid or ester thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils with ethylene oxide, required to be part of the formulation.
A formulation suited to transdermal application whether as an ointment, cream or lotion or in the form of a skin patch providing a reservoir for the ‘ 40 formulation is also a preferred form of the formulation according to the invention,
The essential fatty acid, or ester thereof, component of the composition preferably comprises a mixture of esters of the fatty acids listed above. :
Thus, in the most preferred form of the invention the fatty acid component of the composition is constituted by the complex known as
Vitamin F and in this regard it is preferred to make use of the ester form of Vitamin F known as Vitamin F Ethyl Ester. This product is commercially available under the trade description of Vitamin F Ethyl Ester CLR 110 000
Sh.L. U./g from CLR Chemicals Laboratorium Dr.Kurt Richter GmbH of
Berlin, Germany. The typical fatty acid distribution of this product is as follows: < Ces: 0
Cie0 . 8,3 %
Cigo: 3,5 %
Cig1:21,7%
Cig2 : 34,8 %
Cigs . 28,0 % > Cis: 1,6 % unknown: 2,1 %
It is further preferred to add to the formulation the long chain fatty acids known as eicosapentaenoic acid [C20:50w3] and decosahexaenoic acid [C22:6w3]. Such a product combination is available from Roche Lipid
Technology under the trade name "Ropufa '30' n-3 oil".
It has been found by microscopic studies that the formulation of the anti- infective agents with a medium as herein described gives rise to the formation of minute, generally spherical bodies, within which, or attached to which the active ingredient is contained in a stable form and from which it is delivered at the site of action namely on or inside the infective agent.
The anti-infective agent utilised in the method or formulation according to the present invention may comprise any one or more of the vast spectrum of anti-infective agents as herein defined.
In a preferred form of the invention the anti-infective agent is selected . from the group comprising: 40 the anthelmintics ’ the anti-ectoparasitcides the anti-bacterial agents (including both antibiotics and substances other than antibiotics); the antifungal agents; the anti-viral agents; ; 5 the anti-protozoal agents; the tuberculostatics; the anti-leprotics; the germicides; and the spirochaeticides.
From amongst these anti-infective agents this invention is particularly concerned with the anti-bacterials and the tuberculostatics. These classes of agents overlap to some extent.
The anti-infective agent may in a specific application of the invention comprise an antimicrobial of the class of compounds known as the tuberculostatics or anti-mycobacterial compounds and may specifically be selected from the group consisting of Rifampicin, Isoniazid, Pyrazinamide,
Ethambutol and combinations of any two or more of these.
It is a further aspect of the invention that the formulation, and specifically, though not exclusively, the anti-TB formulation of the invention, may be prepared to be adapted for pulmonary administration.
In the case of the anti-TB formulation it will thereby bring the formulation into contact with the pathogen at a primary locus thereof and without passage through, or absorption from the digestive tract and possible subsequent passage through the liver.
The invention has not yet been demonstrated by empirical work to be applicable to all the agents listed below. However in respect of such anti- infective agents which have already been formulated with the aforementioned administration medium of the invention, and evaluated by different methods for the anticipated enhancement of anti-infective action, no negative result has as yet been seen despite the chemical diversity of the anti-infective agents which has been investigated. The applicant thus confidently expects, on the basis of the observations in ’ respect of products representing a range of classes of such agents, that the invention will find general application across the entire spectrum of . 40 anti-infective agents embraced by the term as herein defined and of which some examples are set out below. It is part of the applicant's present postulations by which it seeks to find an understanding of the invention and to which it does not wish to be bound at this stage, that while the administration medium of the present invention serves to : transport the anti-infective agent formulated therewith most efficiently through the human or animal body, that medium also plays an important role in transferring, by an as yet unexplained mechanism, the anti- ) infective agent through the outer membranes of and into the pathogenic organism thereby to cause an effective anti-infective dose of the agent rapidly to be achieved and to be maintained in the organism until it finally succumbs to the effect of the anti-infective agent.
It is in this respect that the applicant believes that the present invention will find general application despite the vast list of agents mentioned below. The following table sets out examples of the specific anti-infective agents with which this invention is concerned will now be identified with reference to the broad classes in which they fall and, in some cases, also with reference the respective indications for which such agents are indicated and, in some cases, further also with reference to the infective agent giving rise to the indication to be addressed which products comprise the following:
A. SULPHONAMIDES 1) Short-acting
SULPHAPYRIDINE- 1) Inflammatory bowel diseases and in rheumatoid arthritis
SULPHADIAZINE- 1) Nocardiosis (Nocardia species) 2) Toxoplasmosis + Pyrimethamine 3) Long term prophylaxis of rheumatic fever
SULPHADIMIDINE-
SULPHAFURAZOLE- 2) Medium-acting:
SULPHAMETHOXAZOLE - 3) Long-acting:
SULPHADIMETHOXINE -
SULPHAMETHOXYDIAZINE-
SULPHAMETHOXYPYRIDAZINE- ] 4) Ultra-Long-acting:
SULFADOXINE-
SULFAMETOPYRAZINE- : 5) Topical sulphonamide:
SILVER SULPHADIAZINE- } 1) Antibacterial in patients with burns
MAFENIDE ACETATE- 1) Antibacterial in patients with burns
SULPHACETAMIDE- 6) Other sulphonamides:
SULPHAGUANIDINE- 1) Gastrointestinal infections
SULPHASALAZINE- 1) Inflammatory bowel diseases and in rheumatoid arthritis
SUCCINYLSULPHATHIAZOLE- 1) Gastrointestinal infections
PHTHALYLSULPHATHIAZOLE- 1) Gastrointestinal infections 7) SULPHONAMIDE COMBINATIONS:
CO-TRIMOXAZOLE (Trimethoprim+ Sulphamethoxazole)- 1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other diseases that are
Methicillin-sensitive (Staphylococcus aureus) 2) Pneumonia, Arthritis, Sinusitis, Otitis that are Penicillin- sensitive (Streptococcus Pneumoniae) 3) Meningitis and Bacteremia (Listeria monocytogenes) 4) Urinary tract infections, Bacteremia, Other infections (Escherichia coli) 5) Urinary tract and other infections (Enterobacter species) 6) Typhoid fever, Paratyphoid fever, Bacteremia, Acute ) gastroenteritis (Salmonella) 7) Acute gastro-enteritis (Shigella) 8) Otitis media, Sinusitis, Pneumonia, Epiglottitis, Meningitis (Haemophilus influenzae) 9) Chancroid (Haemophilus ducreyi) 10) Brucellosis (Brucella) £ Gentamicin : 35 11) Yersiniosis (Yersinia enterocolitica) 12) Cholera (Vibrio cholerae) 13) Meningitis (Flavobacterium meningosepticum) 14) Melioidosis (Pseudomonas pseudomallei)
15) Granuloma inguinale (Calymmatobacterium granulomatis) 16) Legionnaires’ disease (Legionella Pneumophila) : 17) Pulmonary lesions, Brain abscess, Lesions of other organs (Nocardia asteroides) 18) Lymphogranuloma venereum, Trachoma, Inclusion ’ conjunctivitis [blennotthea], Non-specific urethritis,
Cervicitis (Chlamydia trachomatis) 19) Pneumonia in impaired host [Mild or moderate disease,
Moderately severe or severe disease](Pneumocystis carinii)
B. QUINOLONES
B1 FIRST GENERATION
NALIDIXIC ACID (oxolinic acid) 1) Urinary tract infections
CINOXACIN
1) Urinary tract infections
PIPEMIDIC ACID
PIROMIDIC ACID
ACROSOXACIN
QUINOLONES
B2 SECOND GENERATION
CIPROFLOXACIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia, = Osteomyelitis, Cellulitis and Other infections [Methicillin- sensitive and Methicillin-resistant] (Staphylococcus aureus) + Rifampin 2) Urinary tract infection (Enterococcus) 3) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 4) Penicillin-sensitive and Penicillinase-producing gonococcus (Neisseria gonorrhoeae (gonococcus)) 5) Carrier state (Post-treatment) (Neisseria meningitidis (meningococcus)) : 6) Urinary tract infection and other infections, Bacteremia . (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract and other infections (Enterobacter species)
WO (12/05850 PCT/ZA01/00098 9) Urinary tract infection, Pneumonia, Bacteremia ; (Pseudomonas aeruginosa) 10) Urinary tract infection (Klebsiella pneumoniae) . 11) Typhoid fever, Paratyphoid fever, Bacteremia, Acute gastroenteritis (Salmonella) 12) Acute gastroenteritis (Shigella) 13) Otitis media, Sinusitis, Pneumonia (Haemophilus influenze) 14) Chancrois (Hameophilus ducreyi) 15) Plague (Yersinia pestis) 16) Yersomopsis Sepsis (Yersinia enterocolitica) 17) Tualermia (Francisella tularensis) 18) Cholera (Vibrio tularensis) 19) Enteritis (Campulobacter jejuni) 20) Bacteremia, Endocarditis (Campylbacter fetus) 21) Legionnaires’ disease (Legionella pneumophila) 22) Disseminated disease in AIDS (Mycobacterium avium — intracellulare) + Clarithromycin; £ Ethambutol; +
Clofamizine
OFLOXACIN
1) Penicillin-Sensitive and Penicillinase-Producing gonococcus (Neisseria gonorrhoeae (gonococcus)) 2) Urinary tract infection and other infections, Bacteremia (Escherichia coli) 3) Urinary tract and Other infections (Proteus mirabilis) 4) Urinary tract and Other infections (Enterobacter species) 5) Urinary tract infection (Klebsiella pneumoniae) 6) Typhoid fever, Paratyphoid fever, Bacteremia, Acute gastroenteritis (Salmonella) 7) Urinary tract infection (Pseudomonas aeruginosa) 8) Yersiniosis, Sepsis (Yersinia enterocolitica) 9) Cholera (Vibrio cholerae) 10) Enteritis (Campylobacter jejuni) 11) Bacteremia, Endocarditis (Campylobacter fetus) 12) Leprosy (Mycobacterium leprae) ’ NORFLOXACIN 1) Acute gastroenteritis (Salmonella) : 2) Acute gastroenteritis (Shigella)
ENOXACIN ]
LOMEFLOXACIN
PEFLOXACIN
AMIFLOXACIN
FLEROXACIN
LEVOFLOXACIN
NADIFLOXACIN
RUFLOXACIN
SPARFLOXACIN
1) Active against Streptococcus pneumoniae and anaerobic bacteria.
TOSUFLOXACIN
ENROFLOXACIN
C. Anti-Septic and Analgesic Agents for Urinary Tract Infections
METHENAMIN
1) Not a primary drug for the treatment of acute urinary tract infections, but it is of value for chronic suppressive treatment.
NITROFURANTOIN
1) Urinary tract infection (Escherichia coli)
MENAZOPYRIDINE
1) Is not a urinary antiseptic but it does have an analgesic action on the urinary tract and alleviates symptoms of dysuria, . frequency, burning and urgency.
D. PENICILLIN
NARROW SPECTRUM i
BENZYLPENICILLIN (Penicillin G) [acid-labile]
1) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and Other systemic infections (Streptococcus . pyogenes [Group Al) 2) Endocarditis, Bacteremia (Streptococcus [viridans group]) + Gentamicin. 3) Bacteremia, Endocarditis, Meningitis. (Streptococcus agalactiae [Group B]) + Aminoglycoside. 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin — Sensitive and Penicillin — Resistant] Endocarditis, Meningitis, other serious infections [Penicillin Sensitive] (Streptococcus pneumoniae [pneumococcus]) 6) Endocarditis or other serious infections (bacteremia),
Urinary tract infections (Enterococcus) + Gentamicin 7) Penicillin — sensitive gonococcus (Neisseria gonorrhoeae) : + Probenecid. 8) Meningitis (Neisseria meningitidis [meningococcus]) 9) “Malignant pustule”, Pneumonia (Bacillus anthracis) 10) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species, aerobic and anaerobic [diphtheroids]) = an Aminoglycoside or + Rifampin 11) Meningitis, Bacteremia (Listeria monocytogenes) =
Gentamicin 12) Erysipeloid (Erysipelothrix rhusiopathiae) 13) Gas gangrene (Clostridium perfringens and other species) 14) Tetanus (Clostridium tetani) 15) Urinary tract infection, Bacteremia, Other infections (Escherichia coli) + a Penicillinase inhibitor. 16) Urinary tract and other infections (Proteus, other species) + a B — Lactamase inhibitor 17) Wound infection (animal bites), Abscesses, Bacteremia,
Meningitis (Pasteurella multocida) 18) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 19) Bacteremia, Arthritis, Endocarditis, Abscesses (Streptobacillus moniliformis) 20) Syphilis (Treponema pallidum) . 40 21) Yaws (Treponema pertenue) 22) Stage 2 - neurological, Cardiac, Arthritis (Borrelia burgdorferi [Lyme disease]) 23) Relapsing fever (Borrelia recurrentis)
24) Weil's disease, Meningitis (Leptospira) 25) Cervicofacial, Abdominal, Thoracic, and other lesions (Actinomyces israelii)
PHENOXYMETHYI-PENICILLIN ’ (Penicillin V) [acid — stable] 1) Pharyngitis, Scarlet Fever, Otitis Media, Sinusitis, Cellulitis, : Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome, and other systemic infections (Streptococcus pyogenes [Group A]) 2) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin — Sensitive and Penicillin ~ Resistant] Endocarditis, Meningitis, other serious infections [Penicillin —sensitive] (Streptococcus pneumoniae [pneumococcus]) 3) Urinary tract infections (Enterococccus) 4) Urinary tract infection, Bacteremia, Other infections (Escherichia coli) + a Penicillinase-inhibitor. 5) Urinary tract and other infections (Proteus, other species) + a B — Lactamase inhibitor
E. PENICILLIN
BROAD SPECTRUM
AMOXICILLIN
1) Pharyngitis, Scarlet Fever, Otitis Media, Sinusitis,
Cellulitis, Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [group A]) 2) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin — Sensitive and Penicillin — Resistant] (Streptococcus pneumoniae [Pneumococcus]) 3) Urinary tract and other infections (Proteus mirabilis) . 4) Otitis Media, Sinusitis, Pneumonia (Haemophilus influenzae) + Clavulanic acid. 5) Wound — infection (animal bites), Abscesses, Bacteremia, ’
Meningitis (Pasteurella multocida) + Clavulanic acid 6) Erythema chronica migrans — skin (Borrelia burgdorferi [Lyme disease])
7) Pulmonary lesions, Brain abscess, Lesions of other organs (Nocardia asteroides) + Clavulanic acid 8) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) +
Clavulanic acid 9) Penicillin — Sensitive gonococcus (Neisseria gonorrhoeae) + Probenecid
AMPICILLIN
1) Bacteremia, Endocarditis, Meningitis (Streptococcus agalactiae [Group Bl) 2) Urinary tract infection, Endocarditis, or Other serious infections [Bacteremia] (Enterococcus) 3) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) +
Clavulanic acid 4) Penicillin — Sensitive gonococcus (Neisseria gonorrhoeae) + Probenecid 5) Meningitis, Bacteremia (Listeria monocytogenes) 6) Urinary tract infection, Other infections, Bacteremia (Escherichia coli) + an Amihoglycoside 7) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species, aerobic and anaerobic [diphtheroids]) + Sulbactam 8) Urinary tract and other infections (Proteus mirabilis) 9) Typhoid Fever, Paratyphoid Fever, Bacteremia, Acute
Gastroenteritis (Salmonella) 10) Acute Gastroenteritis (Shigella) 11) Epiglottitis, Meningitis (Haemophilus influenza) +
Sulbactam 12) Bacteremia, Endocarditis, Meningitis (Campylobacter fetus) 13) Cervicofacial, Abdominal, Thoracic, an Other lesions (Actinomyces israeli)
TICARCILLIN
1) Urinary tract and other infections (Enterobacter species) 2) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside 3) Urinary tract infection (Pseudomonas aeruginosa) . 40 4) Variety of nosocomial and opportunistic infections (Serratia) + an Aminoglycoside
PIPERACILLIN
1) Urinary tract and other infections (Enterobacter species) 2) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside 3) Urinary tract infection (Pseudomonas aeruginosa) 4) Variety of nosocomial and opportunistic infections (Serratia) + an Aminoglycoside
MEZLOCILLIN
1) Urinary tract and other infections (Enterobacter species) 2) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside : 3) Urinary tract infection (Pseudomonas aeruginosa) 4) Variety of nosocomial and opportunistic infections (Serratia) + an Aminoglycoside
AZLOCILLIN
1) Urinary tract and Other infections (Enterobacter species) 2) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside 3) Urinary tract infection (Pseudomonas aeruginosa) 4) Variety of nosocomial and opportunistic infections (Serratia) + an Amihoglycoside
BACAMPICILLIN
} TALAMPICILLIN
PIVAMPICILLIN
CARBENICILLIN
APALCILLIN
CARINDACILLIN
PIVMECILLINAM
CARFECILLIN
METAAMPICILLIN
HETACILLIN
TEMOCILLIN
F. PENICILLIN
PENICILLINASE — RESISTANT PENICILLINS (isoxazoly penicillins)
OXACILLIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis, and Other Staphylococcus aureus infections [methicillin — sensitive] (Staphylococcus aureus)
CLOXACILLIN
1) Effective against Penicillinase — Producing Staphylococcus aureus
DICLOXACILLIN
1) Effective against Penicillinase — Producing Staphylococcus aureus
FLUCLOXACILLIN
1) Effective against Penicillinase — Producing Staphylococcus i aureus
METHICILLIN
‘ 1) Effective against Penicillinase — Producing Staphylococcus aureus
NAFCILLIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis, and Other Staphylococcus aureus infections [methicillin-sensitive] (Staphylococcus aureus) @G. CEPHALOSPORINS
G1. FIRST GENERATION
CEPHAZOLIN / CEPHRADINE 1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group A]) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group Bl) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin -
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEPHALORIDINE
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus } aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like ' 40 syndrome and other systemic infections (Streptococcus pyogenes [Group A])
3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B]) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) : 5 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin -
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEPHRADINE
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group A]) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group BI) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin ~
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 40 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEFROXADINE
1) Abscesses, Bacteremia, Endocarditis, Pneumonia, :
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group A]) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B]) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin —
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEFADROXIL
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin ~ Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group A]) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B]) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 40 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin —
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli)
7) Urinary tract and other infections (Proteus mirabilis) : 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CETATRIAZINE
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock - like syndrome and other systemic infections (Streptococcus pyogenes [Group Al) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B)) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5 Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin ~
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia, : Meningitis (Pasteurella Multiocida) ee 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEFALEXIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus : 40 aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock - like syndrome and other systemic infections (Streptococcus pyogenes [Group Al) } 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group BJ) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin —
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
PIVCEPHALEXIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group Al) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B]) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin —
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) £ an Aminoglycoside 40 10) Wound infection (animal bite), Abscesses, Bacteremia, :
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum)
12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEFPROZIL
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome and other systemic infections (Streptococcus pyogenes [Group Al) 3) Bacteremia, Endocarditis (Streptococcus agalactiae [Group B]) 4) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 5) Pneumonia, Arthritis, Sinusitis, Otitis media [Penicillin -
Sensitive] (Streptococcus Pneumoniae [Pneumococcus]) 6) Urinary tract infection, other infections, Bacteremia (Escherichia coli) 7) Urinary tract and other infections (Proteus mirabilis) 8) Urinary tract infection (Klebsiella pneumoniae) 9) Pneumonia (Klebsiella pneumoniae) = an Aminoglycoside 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella Multiocida) 11) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 12) “Malignant Pustule” Pneumonia (Bacillus anthracis)
CEPHALOSPORINS
G2 SECOND GENERATION
CEFOXITIN
1) Penicillin — Sensitive and Penicillinase — Producing gonococcus (Neisseria gonorrhoeae) 2) Gas gangrene (Clostridium perfringens and other species) 3) Variety of nosocomial and opportunistic infections 4) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum)
CEFOTETAN
1) Gas gangrene (Clostridium perfringens and other species) 40 2) Variety of nosocomial and opportunistic infections
CEFUROXIME AXETIL : 1) Otitis media, Sinusitis, Pneumonia (Haemophilus influenza)
CEPHAMANDOLE
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) : 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) + an Aminoglycoside
CEFUROXIME
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) + an Aminoglycoside
CEFONICID
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) + an Aminoglycoside
CEFORANIDE
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) £ an Aminoglycoside
CEFOTIAM
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) + an Aminoglycoside
CEFAMYCINS : : 1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) ~ 3) Urinary tract infection (Klebsiella Pneumoniae) en 4) Pneumonia (Klebsiella Pneumoniae) £ an Aminoglycoside
CEFACLOR
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus mirabilis) 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) £ an Aminoglycoside
LORACARBEF i 1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 40 2) Urinary tract and other infections (Proteus mirabilis) : 3) Urinary tract infection (Klebsiella Pneumoniae) 4) Pneumonia (Klebsiella Pneumoniae) + an Aminoglycoside
CEPHALOSPORINS
: G3 THIRD GENERATION
CEFTRIAXONE
1) Endocarditis, Bacteremia (Streptococcus [Viridans Group]) 2) Meningitis (Streptococcus agalactiae [Group B]) 3) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin
Resistant] (Streptococcus pneumoniae [Pneumonococcus]) 4) Endocarditis, Meningitis, Other serious infections [Penicillin intermediate- resistant and Penicillin ~
Sensitive] (Streptococcus Pneumoniae) 5) Penicillin — Sensitive and Penicillin Producing gonococcus (Neisseria gonorrhoeae [gonococcus]) 6) Meningitis (Neisseria meningitidis [meningococcus]) 7) Typhoid fever, Paratyphoid fever, Bacteremia (Salmonella) 8) Epiglottis, Meningitis (Haemophilus influenzae) 9) Chancroid (Haemophilus ducreyi) 10) Wound infection (animal bite), Abscesses, Bacteremia,
Meningitis (Pasteurella multocida) 11) Melioidosis (Pseudomonas pseudomallei) 12) Bacteremia, Endocarditis, Meningitis (Campylobacter fetus) 13) Syphilis (Treponema pallidum) 14) Erythema chronica migrans ~ skin, Stage 2 — neurological,
Cardiac, Arthritis (Borrelia burgdorferi [Lyme disease]) 15) Pulmonary lesions, Brain abscess, Lesions of other organs (Nocardia asteroides)
CEFOTAXIME
1) Meningitis (Streptococcus agalactiae [Group BJ) 2) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin -
Resistant] (Streptococcus pneumoniae [Pneumonococcus]) 3) Endocarditis, Meningitis, Other serious infections [Penicillin intermediately- Resistant and Penicillin —
Sensitive] (Streptococcus Pneumoniae) 4) Endocarditis, Meningitis, Other serious infection [Penicillin
G — Resistant] (Streptococcus pneumoniae) + Rifampin or : + Vancomycin 40 5) Meningitis (Neisseria meningitidis [meningococcus]) 6) Epiglottits, Meningitis (Haemophilus influenzae)
CEFTIZOXIME
1) Gas gangrene (Clostridium perfringens and other species)
CEFIXIME : 1) Penicillin — Sensitive and Penicillinase - Producing gonococcus (Neisseria gonorrhoeae)
CEFTAZIDIME
1) Urinary tract infection (Pseudomas aeruginosa) 2) Pneumonia, Bacteremia Pseudomonas aeruginosa + an
Aminoglycoside 3) Melioidosis (Pseudomonas pseudomallei)
CEFMENOXIME
1) Otitis, Sinusitis, Pneumonia (Moraxella Catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFODIZIME
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFDINIR
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia) 40 CEFETAMET PIVOXIL : 1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis)
4) Urinary tract infection (Klebsiella pneumoniae) : 5) Pneumonia (Klebsiella pneumoniae) £ an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFTIBUTEN
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
LATAMOXEF (OXACEPHALOSPORIN) 1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFPIRAMIDE
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFSULODIN
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) : 2) Urinary tract and other infections (Proteus, other species) 40 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside
6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEFOPERAZONE
1) Otitis, Sinusitis, Pneumonia (Moraxella catarrhalis) 2) Urinary tract and other infections (Proteus, other species) 3) Urinary tract and other infections (Proteus mirabilis) 4) Urinary tract infection (Klebsiella pneumoniae) 5) Pneumonia (Klebsiella pneumoniae) + an Aminoglycoside 6) Various nosocomial infections (Acinetobacter) 7) Yersiniosis, Sepsis (Yersinia enterocolitica) 8) Variety of nosocomial and opportunistic infections (Serratia)
CEPHALOSPORINS
G4 FOURTH GENERATION
CEFEPIME
1) Active against many Enterobacteriaceae that are resistant to other cephalosporins 2) Active against H. influenzae, N. gonorrhoeae and N. meningitidis 3) High activity for streptococci and Methicillin-Sensitive
Staphylococcus aureus 4) Also active against P. aeruginosa and Xanthomonas maltophilia
H. OTHER B-LACTAM ANTIBIOTICS CARBAPENEMS
IMIPENEM
1) Gas gangrene (Clostridium perfringens and other species) 2) Urinary tract and other infections (Enterobacter species) 3) Urinary tract and other infections (Proteus, other species) 4) Urinary tract infection (Pseudomonas aeruginosa) 5) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside 6) Pneumonia (Klebsiella pneumoniae) 7) Variety of nosocomial and opportunistic infections 40 (Serratia) : 8) Various nosocomial infections (Acinetobacter) 9) Bacteremia, Endocarditis (Campylobacter fetus)
10) Pulmonary lesions, Brain abscess, Lesions of other organs : (Nocardia asteroides)
MEROPENEM
1) Active against some Imipenem — Resistant Pseudomonas aeruginosa 2) Urinary tract infection (Pseudomonas aeruginosa)
I. OTHER f — LACTAM ANTIBIOTICS
MONOBAKTAMS
AZTREONAM
1) Urinary tract infection, Other infections, Bacteremia (Escherichia coli) 2) Urinary tract and Other infections (Proteus, other species) 3) Urinary tract infection (Pseudomonas aeruginosa) 4) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + an
Aminoglycoside 5) Pneumonia (Klebsiella pneumoniae) 6) Variety of nosocomial and opportunistic infections (Serratia)
J. AMINOGLYCOSIDE
STREPTOMYCIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) £ Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 40 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica)
12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic : [diptheroids]) + Penicillin G 13) Bacteremia, Arthritis, Endocarditis, Abscesses (Streptobacillus moniliformis) 14) Pulmonary, Milary, Renal, Meningeal, and other tuberculous infections (Mycobacterium tuberculosis) +
Rifampin or Ethambutol 15) Yaws (Treponema pertenue) 16) Plague (Yersinia pestis) + Tetracycline 17) Tularemia (Francisella tularensis) 18) Glanders (Pseudomonas mallei) + a Tetracycline or +
Chloramphenicol 19) Occasionally administrate for tuberculosis (Mycobacterium tuberculosis)
GENTAMICIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) £ Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G 13) Endocarditis or other serious infection [bacteremia] 40 (Enterococcus) +Penicillin G or Ampicillin; +Vancomycin : 14) Meningitis, Bacteremia (Listeria monocytogenes) +
Ampicillin or Penicillin G 15) Brucellosis (Brucella) + Doxycycline
16) Tularemia (Francisella tularensis) 17) Bacteremia, Endocarditis (Campylobacter fetus)
TOBRAMYCIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) £ Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G
AMICACIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) + Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 40 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin
10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G 13) Disseminated disease in AIDS (Mycobacterium avium — intracellulare) 14) Pulmonary lesions, Brain abscess, Lesions of the other organs
NETILMICIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) = Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) : 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G 13) Effective against certain gentamicin-resistant pathogens, except enterococci
KANAMYCIN
: 1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) = Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 40 3) Urinary tract infection and other infections (Proteus : mirabilis) 4) Urinary tract infection and other infections (Proteus, other species)
5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocillin or
Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G 13) Orally for the prophylactic use as adjunctive therapy in cases of hepatic coma
NEOMYCIN
1) Urinary tract infection, other infections, Bacteremia. (Escherichia coli) £ Ampicillin 2) Urinary tract infection and other infections (Enterobacter species) 3) Urinary tract infection and other infections (Proteus mirabilis) 4) Urinary tract infection and other infections (Proteus, other species) 5) Urinary tract infection (Pseudomonas aeruginosa) 6) Pneumonia, Bacteremia (Pseudomonas aeruginosa) + A broad-spectrum Penicillin; + Ciprofloxacin; + Ceftazidime; + Aztreonam; + Imipenem 7) Urinary tract infection (Klebsiella pneumoniae) 8) Pneumonia (Klebsiella pneumoniae) + Mezlocilin or —— Piperacillin 9) Variety of nosocomial and opportunistic infections (Serratia) + A broad-spectrum Penicillin 10) Various nosocomial infections (Acinetobacter) 11) Sepsis (Yersinia enterocolitica) 12) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species; aerobic and anaerobic [diptheroids]) + Penicillin G 40 13) For bladder irrigation + Polymyxin B 14) Variety of infections of the skin and mucous membranes caused by microorganisms susceptible to the drug. These include infections associated with burns, wounds, ulcers, and infection dermatoses.
K. TETRACYCLINE
TETRACYCLINE
1) Sinusitis (Moraxella catarrhalis) 2) Plague (Yersinia pestis) + Streptomycin 3) Glanders (Pseudomonas mallei) + Streptomycin 4) Stage 2 - Neurological, cardiac, arthritis (Borrelia burgdorferi [Lyme disease])
CHLORTETRACYCLINE
OXYTETRACYCLINE
DOXYCYCLINE
1) Erysipeloid (Erysipelothrix rhusiopathiae) 2) Gas gangrene (Clostridium perfringens & other species) 3) Tetanus (Clostridium tetani) 5) Urinary tract infection (Escherichia coli) 5) Brucellosis (Brucella) + Gentamicin or Rifampin 6) Chancriod (Haemophilus ducreyi) 7) Plague (Yersinia pestis) 8) - Wound infection-animal bite (Pasteurella multocida) 9) Cholera (Vibrio cholerae) 10) Lung abscess, empyema (Fusobacterium nucleatum) 11) Arthritis (Streptobacillus moniliformis) 12) Syphilis (Treponema pallidum) 13) Yaws (Treponema pertenue) 14) Erythema chronica migrans-skin (Borrelia burgdorferi[Lyme disease]) 15) Relapsing fever (Borrelia recurrentis) 16) Weil's disease and meningitis (Leptospira) 17) Cervicofacial, abdominal, thoracic, and other lesions (Actinomyces israeli) 18) Non-specific urethritis (Ureaplasma urealyticum) 19) “Atypical pneumonia” (Mycoplasma pneumoniae) 20) Typhus fever, Murine typhus, Brill's disease, Rocky
Mountain spotted fever, Q fever, and Rickettsialpox (Rickettsia) 21) Psittacosis (Chlamydia psittaci) 22) Lymphogranuloma venereum, Trachoma, Inclusion conjunctivitis (blennorrhea), Non-specific urethritis, 40 Cervicitis (Chlamydia trachomatis) 23) Pneumonia (Chlamydia pneumoniae)
MINOCYCLINE
DEMECLOCYCLINE
METHACYCLINE
L CHLORAMPHENICOL
CHLORAMPHENICOL
1) Meningitis (Streptococcus agalactiae [Group B]) 2) Bacteremia, Endocarditis, Brain and other abscesses, and
Sinusitis (Streptococcus [anaerobic species]) 3) Pneumonia, Arthritis, Sinusitis, Otitis, Endocarditis,
Meningitis, Other serious infections (Streptococcus pneumoniae [pneumonococcus]). 4) Meningitis (Neisseria meningitidis [meningococcus]) 5) “Malignant pustule”, Pneumonia (Bacillus anthracis) 6) Bacteremia (Listeria monocytogenes) 7) Erysipeloid (Erysipelothrix rhusiophathiae) 8) Gas gangrene (Clostridium perfringens and other species) 9) Typhoid fever, Paratyphoid fever, Bacteremia (Salmonella) 10) Epiglottitis, Meningitis (Haemophilus influenza) 11) Brucellosis (Brucella) 12) Plague (Yersinia pestis) 13) Sepsis (Yersinia enterocolitica) 14) Tularemia (Francisella tularensis) 15) Cholera (Vibrio cholerae) 16) Glanders (Pseudomonas mallei) + Streptomycin 17) Melioidosis (Pseudomonas pseudomallei) 18) Meningitis (Campylobacter fetus) 19) Ulcerative pharyngitis, Lung abscess and Empyema,
Genital infections, Gingivitis (Fusobacterium nucleatum) 20) Bacteremia, Arthritis, Endocarditis, Abscesses (Streptobacillus moniliformis) 21) Typhus fever, Murine typhus, Brill's disease, Rocky mountain spotted fever, Q fever, Rickettsialpox (Rickettsia) 22) Psittacosis [ornithosis] (Chlamydia psittaci)
THIAMPHENICOL
AZIDAMPHENICOL
40 M. ERYTHROMYCIN AND OTHERS
MACROLIDES:
ERYTHROMYCIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia
Osteomyelitis, Cellulitis and other Staph. aureus infections [Methicillin — Sensitive] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, toxic shock — like syndrome, and other systemic infections (Streptococcus pyogenes [Group AJ) 3) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 4) Penicillin — Sensitive gonococcus (Neisseria gonorrhoeae) 5) “Malignant pustule”, Pneumonia (Bacillus anthracis) 6) Pharyngitis, Laryngotracheitis, Pneumonia, and other local lesions, Carrier state (Corynebacterium diptheriae) 7) Bacteremia (Listeria monocytogenes) 8) Chancroid (Haemophilus ducreyi) 9) Enteritis (Campylobacter jejuni) 10) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis (Fusobacterium nucleatum) 11) Bacteremia, Arthritis, Endocarditis, Abscesses (Streptobacillus moniliformis) 12) Legionnaires’ disease (Legionella pneumophila) + rifampin 13) Relapsing fever (Borrelia recurrentis) 14) Cervicofacial, Abdominal, Thoracic and other lesions (Actinomyces israeli). 15) Non-specific Urethritis (Ureaplasma Urealyticum) 16) “Atypical pneumonia” (Mycoplasma pneumoniae) 17) Lymphogranuloma venereum, Trachoma, Inclusion conjunctivitis [blennorrhea], Non-specific urethritis,
N oo . Ceyvicitis (Chlamydia trachomatis)
Ea . 18) Pneumonia (Chlamydia pneumoniae) 19) Erysipeloid (Erysipelothrix rhusiopathiae) 20) Bordetella pertussis disease and for post-exposure : prophylaxis of all household member and other close contacts. 21) Tetanus in patients who are allergic to penicillin (Clostridium tetani) 40 CLARITHROMYCIN 1) Legionnaires’ disease (Legionella pneumophila) 2) “Atypical pneumonia” (Mycoplasma pneumoniae) 3) Pneumonia (Chlamydia pneumoniae)
4) Enteritis (Campylobacter jejuni) 5) Disseminated disease in AIDS (Mycobacterium avium — intracellulare) + Ethambutol; + Clofazimine; +
Ciprofioxacin 6) Erythema chronica migrans — skin (Borrelia burgdorferi [Lyme disease]) 7) Modest activity against H. influenzae and N. gonorrhoeae 8) Good activity against M. catarrhalis 9) Enhanced activity against some protozoa (e.g,
Toxoplasma gondii, Cryptoporidium and Plasmodium spp. 10) Regimens for the treatment of peptic ulcers related to H. pylori infection 11) Lepromatous leprosy (Mycobacterium leprae) + minocycline
AZITHROMYCIN
1) Otitis media, Sinusitis, Pneumonia (Haemophilus influenzae) 2) Enteritis (Campylobacter jejuni) 3) Legionnaires’ disease (Legionella pneumophila) 4) Erythema chronica migrans — skin (Borrelia burgdorferi [Lyme disease]) 5) “Atypical pneumonia” (Mycoplasma pneumoniae) 6) Lymphogranuloma venereum, Trachoma, Inclusion conjunctivitis [blennorrhea], Non-specific urethritis,
Cervicitis (Chlamydia trachomatis) 7) Pneumonia (Chlamydia pneumoniae) 8) Less active against Streptococcus spp. And Enterococci 9) Active against M. catarrhals, Pasteurella multocida,
Fusobacterium spp., N. gonorrhoeae 10) Enhanced activity against Mycobacterium avium- intracellulare, as well as against protozoa (e.g.
Toxoplasma gondii, Crytosporidium and Plasmodium spp. 11) Toxoplasmosis encephalitis and diarrhoea due to
Cryptosporidium
ROXITHROMYCIN
N. LINCOMYCIN : 40 CLINDAMYCIN 1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive] (Staphylococcus aureus). 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome, and other systemic infections (Streptococcus pyogenes [Group Al) 3) Bacteremia, Endocarditis, Brain and other abscesses,
Sinusitis (Streptococcus [anaerobic species]) 4) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin — Sensitive and Penicillin — Resistant] (Streptococcus pneumoniae) 5) Pharyngitis, Laryngotracheitis, Pneumonia, Other local lesions (Corynebacterium diphteriae) 6) Gas gangrene (Clostridium perfringens and other species) 7) Tetanus (Clostridium tetani) 8) Enteritis (Campylobacter jejuni) 9) Ulcerative pharyngitis, Lung abscess, Empyema, Genital infections, Gingivitis 10) Pneumonia in impaired host [Mild or moderate disease and moderately severe or severe disease] (Pneumocystis carinii) + Primaquin 11) Treatment of infections with anaerobes, especially those due to B. fragilis 12) Intra-abdominal or pelvic abscesses and peritonitis + an
Aminoglycoside or + Penicillin or + Cephalothin 13) Topically or orally for acne vulgaris and for bacterial vagionosis
SPECTINOMYCIN
1) Penicillin - Sensitive and Penicillinase-Producing gonococcus (Neisseria gonorrhoeae) 2) In pregnancy when patients are intolerant to B-Lactams and when quinolones are contraindicated 3) Recommended as an alternative regimen in patients who are intolerant or allergic to B-Lactam antibiotics and 33 quinolones
POLYMYXIN B (Polymyxin B Sulfate) 1) Available for ophthalmic, otic and topical use in combination with a variety of other compounds. 2) Infections of the skin, mucous membranes, eye, and ear : 40 due to polymyxin B — sensitive microorganisms 3) External otitis, frequently due to pseudomonas 4) Infection of corneal ulcers (Pseudomonas aeruginosa)
Pneumonia (Pseudomonas)
COLISTIN (Colisten Sulfate) 1) Diarrhoea caused by bacteria susceptible to the drug in infants and children 5 RAMOPLANIN (glycopeptide) 1) Treatment of acne and skin infections, and to reduce nasal carriage of staphylococci
Active against Bacteroides spp.
TEICOPLANIN (glycopeptide) 1) Osteomyelitis, Endocarditis caused by Methicillin -
Resistant and Methicillin — Susceptible Staphylococci,
Streptococci and Enterococci 2) Bacteremia, Endocarditis [methicillin — susceptible] (Staphylococcus aureus) + an Aminoglycoside [gentamycin] 3) Enterococcal endocarditis + Gentamicin 4) Endocarditis + Vancomycin
BACITRACIN
1) Infected eczema, Infected dermal ulcers 2) Suppurative conjunctivitis and infected corneal ulcer when they are cause by susceptible bacteria 3) Eradication of nasal carriage of Staphylococci 4) Antibiotic — associated diarrhoea (Clostridium difficile) .
RP 59500 1) Is a good inducer of the methylase enzyme that mediates
MLS resistance 2) Are synergistic and therefore, erythromycin-resistant organisms frequently are susceptible to RP 59500 in vitro
GLYCYLCYCLINES (Tetracycline Antibiotic derivatives) 1) They inhibit some tetracycline-resistant organisms 2) Also appear to be active against multiply drug-resistant strains of Staphylococci, pneumacocci and vancomycin- resistant enterococci
GLYCOPEPTIDE AND OTHER:
VANCOMYCIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis and other Staphylococcus aureus infections [Methicillin — Sensitive and Methicillin Resistant] (Staphylococcus aureus) 2) Pharyngitis, Scarlet fever, Otitis media, Sinusitis, Cellulitis,
Erysipelas, Pneumonia, Bacteremia, Toxic shock — like syndrome, and other systemic infections (Streptococcus pyogenes [Group A]) 3) Endocarditis, Bacteremia (Streptococcus [Viridans Group]) 4) Bacteremia, Endocarditis (Streptococcus agalactiae [
Group B]) 5) Pneumonia, Arthritis, Sinusitis, Otitis [Penicillin —
Resistant] (Streptococcus pneumoniae). 6) Endocarditis, Meningitis, Other serious infections [Penicillin — intermediately Resistant] (Streptococcus pneumoniae) + Rifampin 7) Endocarditis, Meningitis, Other serious infections [Penicillin G — Resistant] (Streptococcus pneumoniae) +
Rifampin or + Cefotaxime 8) Endocarditis or other serious infection [bacteremia] (Enterococcus) + Gentamincin 9) Urinary tract infection (Enterococcus) 10) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species, aerobic and anaerobic [diptheroids]) 11) Tetanus (Clostridium tetani) 12) Antibiotic — associated colitis (Clostridium difficile) 13) Meningitis (Flavobacterium meningosepticum) 14) Pseudomembranous colitis 15) Staphylococcal infections in patients who are allergic to penicillins and cephalosporins 0. Drugs Used in the Treatment of Tuberculosis, Mycobacterium avium
Complex, and Leprosy
AMIKACIN
AMINOSALICYCLIC ACID
AZITHROMYCIN
CAPREOMYCIN
CEFOXITIN
CIPOFLOXACIN
40 CLARITHROMYCIN
CLOFAZIMINE
DAPSONE
DOXYCYCLINE
ETHAMBUTOL
ETHIONAMIDE
IMIPENEM
ISONIAZID
KANAMYCIN
MINOCYCLINE
OFLOXACIN
OFLOXACIN
PYRAZINAMIDE
RIAMPIN
RIFABUTIN
RIFAMPIN
STREPTOMYCIN
SULFONAMIDE
TRIMETHOPRIM-SULFAMETHOXAZOLE,
P. OTHER TREATMENTS
RIFAMPIN
1) Abscesses, Bacteremia, Endocarditis, Pneumonia,
Osteomyelitis, Cellulitis, Other [Methicillin-Sensitive
Methicillin-Resistant] (Staphylococcus aureus) +
Ciprofloxacin or [+ Trimethoprim-sulfumethoxazole when methicillin-resistant] 2) Endocarditis, Meningitis, Other serious infection [Penicillin-Intermediately resistant] (Streptococcus pneumonia (pneumonococcus)) + Vancomycin 3) Endocarditis, Meningitis, Other serious infection [Penicillin
G-resistant] (Streptococcus pneumoniae (pneumonococcus)) + Cefotaxime or + Vancomycin 4) Carrier state (post-treatment) (Neisseria meningitidis (meningoccoccus)) 5) Pharyngitis, Laryngotracheitis, Pneumonia, Other local lesions (Corynebacterium diphtheriae) 6) Endocarditis, Infected foreign bodies, Bacteremia (Corynebacterium species, aerobic and anaerobic (diphtheroids)) + Penicillin G 7) Brucellosis (Brucella) + Doxycycline or + Trimethoprim 8) Meningitis (Flavobacterium meningosepticum) 9) Legionnaires’ disease (Legionella pneumophila) + : 40 Erythromycin
Q. ANTI-FUNGAL AGENTS
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B
AMPHOTERICIN B,
BUTOCONAZOLE
CICLOPIROX
CICLOPIROX
CLOTRIMAZOLE
CLOTRIMAZOLE
CUTANEOUS
ECONAZOLE
ECONAZOLE
EXTRACUTANEOUS
FLUCONAZOLE
FLUCONAZOLE
FLUCONAZOLE
FLUCONAZOLE
FLUCONAZOLE,
FLUCYTOSINE
GRISEOFULVIN
HALOPROGIN
INTRATHECAL
IODIDE, ITRACONAZOLE
ITRACONAZOLE
ITRACONAZOLE
ITRACONAZOLE,
ITRACONAZOLE,
ITRACONAZOLE,
IV MICONAZOLE
KETOCONAZOLE
KETO-CONAZOLE
KETO-CONAZOLE
KETO-CONAZOLE :
KETOCONAZOLE,
MICONAZOLE
MICONAZOLE
MICONAZOLE NYSTATIN
NAFTIFINE
NYSTATIN
NYSTATIN
SPOROTRICHOSIS
SYSTEMIC
TERBINAFINE
TERBINAFINE
TERCONAZOLE
TIOCONAZOLE
TOPICAL CLOTRIMAZOLE
UNDECYLENATE
R. OTHER TREATMENTS
POLIEEN ANTIBIOTICS
AMPHOTERICIN B
1) Deep infection (Candida species) + Flucytosine 2) Disseminated (non-meningeal), Meningitis (Coccidioides immitis) 3) Chronic Pulmonary disease, Disseminated (Histoplasma capsulatum) 4) All the Blastomyces brasiliensis infections 5 All the paracocidioides brasiliensis infections followed up by a sulfonamide 6) Extracutaneous (Sporothrix schenckii) 7) Invasive (Aspergillus species) 8) All the infections of the mucormycosis Agents 9) Pulmonary (Cryptococcus neoformans) 10) Meningitis (Cryptococcus neoformans) + Flucytosine
NYSTATIN
1) Cutaneous or vaginal thrush, oral thrush (Candida species)
FLUCYTOSINE
1) Deep infections (Candida species) + Amphotericin B 2) Meningitis (Cryptococcus neoformans) + Amphotericin B : POVIDONE IODINE
Povidone-iodine is an iodophore which is used as a disinfectant and antiseptic mainly for the treatment of contaminated wounds and pre-operative preparation of the skin and mucous membranes as well as for the disinfection of equipment.
S. IMIDAZOLES AND TRIAZOLES
KETOCONAZOLE : 1) Cutaneous or vaginal thrush, Oral thrush, (Candida species) 2) Chronic pulmonary disease (Histoplasma capsulatum) 3) All Blastomyces dermatitidis infections. 4) All Paracoccidioides brasiliensis infections
ITRACONAZOLE
1) Cutaneous or vaginal thrush, Oral thrush (Candida species) 2) Disseminated (non-meningeal), Meningitis (Coccidioides immitis) 3) Disseminated (Histoplasma capsulatum) 4) Cutaneous, Extracutaneous (Sporothrix schenckii) 5) Invasive (Aspergillus species) 6) Chronic pulmonary disease (Histoplasma capsulatum) 7) All paracoccidioides brasiliensis infections 8) All Blastomyces dermatitidis infections
FLUXONAZOLE
1) Cutaneous or vaginal thrush, Oral thrush, Deep infection (Candida Species) 2) Disseminated (non-meningeal), Meningitis (Coccidioides immitis) 3) Chronic pulmonary disease (Histoplasma capsulatum) 4) Meningitis (Cryptococcus neoformans)
CLOTRIMAZOLE
1) Oral thrush (Candida Species)
GRISEOFULVIN
1) Mycotic disease of the skin, hair and nails due to
Microsporum, Trichophyton or Epidermophyton 2) Tinea capitis (M. canis, M. audouini; T. schoenleinii and T. verrucosum) 3) “Ringworm” of the glabrous skin, Tinea cruris and tinea : corporis (M. canis, T. rubrum, T. verrucosum and E. floccosum) 40 4) Tinea of the hands (T. rubrum, T. mentagraphytes) 5) Tinea of the beard (Trichopyton species)
6) “Athlete's foot” or epidermophytosis involving the skin and nails (T. mentagraphytes and the hyperkeratotic type to T. rubrum).
T. TOPICAL ANTI-FUNGAL AGENTS
Imidazoles and Triazoles for Topical Use
CLOTRIMAZOLE
1) Dermatophyte infections, Cutaneous candidiasis,
Vulvovaginal candidiasis
ECONAZOLE
MICONAZOLE
1) Tinea pedis, Tinea cruris, Tinea versicolor 2) Vulvovaginal candidiasis 3) Some vaginal infections caused by Candida glabrata
TERCONAZOLE
1) Vaginal Candidiasis
BUTOCONAZOLE
1) Vaginal Candidiasis
TIOCONAZOLE
1) Candida Vulvovaginitis :
OXICONAZOLE
1) Infections caused by the common pathogenic dermatophytes
SULCONAZOLE
1) Infections caused by the common pathogenic dermatophytes
U. OTHER ANTI-FUNGAL AGENTS FOR TOPICAL USE
CICLOPIROX OLAMINE
1) Cutaneous candidiasis, Tinea corporis, Tinea cruris, Tinea
SA pedis, Tinea versicolor 2) Dermatomycoses and candidal infections
HALOPROGIN
1) Tinea pedis, Tinea cruris, Tinea corporis, Tinea manuum and Tinea versicolor
TOLNAFTATE
1) Tinea pedis
NAFTIFINE
: 40 1) Treatment of Tinea cruris and Tinea corporis 2) Cutaneous candidiasis and Tinea versicolor
TERBINAFINE
1) Tinea corporis, Tinea cruris, Tinea pedis }
2) Cutaneous candidiasis and Tinea versicolor 3) Treatment of ringworm and in some cases of onychomycosis
V. MISCELLANEOUS ANTI-FUNGAL AGENTS
UNDECYLENIC ACID
1) Treatment of various dermatomycoses, especially Tinea pedis 2) Treatment of diaper rash, Tinea cruris and other minor dermatologic conditions ~ BENZOIC ACID AND SALICYLIC ACID 1) Treatment of Tinea pedis and sometimes used to treat
Tinea capitis
PROPIONIC ACID AND CAPRYLIC ACID
1) Treatment of the dermatomycoses
POTASSIUM IODIDE
1) Cutaneous (Sporothrix schenckii)
W. ANTI-FUNGAL AGENTS FOR OPHTHALMIC USE
NATAMYCIN
Fungal blepharitis, conjunctivitis, keratitis
IMIDAZOLES CLOTRIMAZOLE
Fungal keratitis
ECONAZOLE
Fungal keratitis
FLUCONAZOLE
Fungal keratitis
KETOCONAZOLE
Fungal keratitis
MICONAZOLE
Fungal keratitis, endophthalmitis
PYRIMIDINES
FLUCYTOSINE
Fungal keratitis
POLYENES
AMPHOTERICIN B
Fungal keratitis, endophthalmitis
X. ANTI-VIRAL AGENTS
ANTI-HERPESVIRUS AGENTS:
ACYCLOVIR
1) Genital disease, Keratoconjunctivitis, Encephalitis,
Neonatal HSV, Mucocutaneous HSV in immuno- compromised host (Herpes simplex virus) 2) Herpes zoster or varicella in immuno-compromised host, pregnancy, Varicella or herpes zoster in normal host (Varicella zoster virus)
VALACYCLOVIR
1) Genital herpes or localised herpes zoster
FAMCICLOVIR
1) Varicella or herpes zoster in normal host (Varicella zoster virus)
PENCICLOVIR
1) It is inhibitory for hepatitis B virus
FOSCARNET
1) Retinitis in patients with AIDS (Cytomegalovirus) 2) Mucocutaneous HSV in immuno-compromised host (Herpes simplex virus) 3) Herpes zoster or varicella in immuno-compromised host, pregnancy (Varicella zoster virus)
GANCICLOVIR
1) Retinitis in patients with AIDS (Cytomegalovirus)
IDOXURIDINE
1) Keratoconjunctivitis (Herpes simplex virus)
SORIVUDINE
1) Herpes zoster in HIV — infected adults
TRIFLURIDINE
1) Keratoconjunctivitis (Herpes simplex virus)
VIDARABINE
1) Encephalitis, neonatal herpes (Herpes simplex virus) ) 2) Zoster or varicella in immuno-compromised patients
Y. ANTI-RETROVIRAL AGENTS
ZIDOVUDINE
1) AIDS, HIV antibody positive and CD4 count less than 500/mm? (Human immuno-deficiency virus) : 40
DIDANOSINE
1) Advanced HIV infections in adults and children over 6 months
STAVUDINE
1) AIDS, HIV antibody positive and CD4 count less than 400/mm? (Human immuno-deficiency virus)
ZALCITABINE
1) AIDS 2) - HIV infection and CD4 count less than 300/mm3
Z, OTHER ANTI-VIRAL AGENTS
AMANTADINE
1) Influenza (Influenza A)
RIMANTADINE
1) Influenza (Influenza A)
INTERFERONS ALFA
1) Genital papilloma (Human papilloma virus)
RIBAVIRIN
1) Pneumonia and bronchiolitis of infancy (Respiratory syncytial virus)
AA. NEWER AGENTS UNDER CLINICAL DEVELOPMENT
LAMIVUDINE
PROTEASE INHIBITORS
ACYCLIC NUCLEOSIDE PHOSPHONATES
AB. ANTI-VIRAL AGENTS FOR OPHTHALMIC USE
IDOXURIDINE (HERPLEX) 1) Herpes simplex keratitis
TRIFLURIDINE (VIROPTIC) : 1) Herpes simplex keratitis
VIDARABINE (VIRA-A) 1) Herpes simplex keratitis 2) Herpes simplex conjunctivitis
ACYCLOVIR (ZOVIRAX) 1) Herpes zoster ophthalmicus 2) Herpes simplex keratitis
FOSCARNET (FOSCAVIR) 1) Cytomegaloviris retinitis
GANCICLOVIR (CYTOVENE) 1) Cytomegaloviris retinitis 40 AC. Topical Antibacterial Agents Commercially Available for Ophthalmic
Use
BACITRACIN ZINC (AK-TRACIN)
1) Conjunctivitis, blepharitis
CHLORAMPHENICOL (AK-CHLOR, CHLOROMYCETIN, CHLOROPTIC,
OCU-CHLOR) 1) Conjunctivitis, keratitis
CHLORTETRACYCLINE HYDROCHLORIDE
(AUREOMYCIN) 1) Conjunctivitis, blepharitis
CIPROFLOXACIN HYDROCHLORIDE (CILOXAN) 1) Conjunctivitis, keratitis
ERYTHROMYCIN (AK-MYCIN, ILOTYCIN) 1) Blepharitis, conjunctivitis
GENTAMICIN SULFATE (GARAMYCIN, GENOTIC, GENT-AK,
GENTACIDIN) 1) Conjunctivitis, blepharitis, keratitis
NORFLOXACIN (CHIBROXIN) 1) Conjunctivitis
SULFACETAMIDE SODIUM
(AK-SULF, BLEPH-10, CETAMIDE, SULF-10, ISOPTO CETAMIDE,
OPHTHACET, SULAMYD SODIUM) 1) Conjunctivitis, blepharitis, keratitis
SULFISOXAZOLE DIOLAMINE (GANTRISIN) 1) Conjunctivitis, blepharitis, keratitis
POLYMYXIN B COMBINATIONS
1) Conjunctivitis, blepharitis, keratitis
TETRACYCLINE HYDROCHLORIDE (ACHROMYCIN) 1) Conjunctivitis, blepharitis
TOBRAMYCIN SULFATE (TOBREX) 1) Conjunctivitis, blepharitis, keratitis
PRELIMINARY HYPOTHESES OF MECHANISM OF OPERATION
The mechanism by which the enhancement of action of anti-infective drugs is achieved by the present invention, is currently under investigation. Some observations in this regard have been recorded above. In addition it is recorded that preliminary observations point to some additional possible explanations. The applicant again does not wish to be bound to any of the tentative explanations it may put forward at this time. It is recorded, however, that it would appear that the long chain fatty acids used in the formulation of the preparation according to the invention, or at least some of these components, form, during the manufacturing process of the medicinal formulation, very small spherical bodies, hereinafter referred to as “nanolipid vesicles”. These nanolipid vesicles have dynamic characteristics in respect of the encapsulation and subsequent delivery of compounds at predicted areas in cells and organisms where the optimal utilisation of these compounds occur with resultant maximised modes of actions.
The present model for the understanding of the invention is that the dynamic delivery characteristics of the nanolipid vesicles are utilised efficiently to transport compounds to locations where maintenance of optimal concentrations in the organisms is beneficial in combating specific infective diseases.
Infectious diseases, especially those which are known to develop resistance to compounds are known to be difficult to treat due to insufficient penetration of the compound into the causative microorganisms. These, or at least some of these appear to be particularly suited for the benefits of the present invention.
The composition of the invention has thus been found to have beneficial drug delivery effects when exposed to cells and causative organisms harboured by such cells.
These beneficial effects are believed to be attributable to the dynamic characteristics of the nanolipid vesicles. The current hypothesis is that these characteristics include: : 1. The structural characteristics of the formulation of the 40 preparation:
Nitrous oxide and the unsaturated long chain fatty acids forming : part of the administration medium are formulated by being mixed with designated anti-infective agents or compounds to form the nanolipid vesicles containing the compound or anti-infective agent.
Two important observations have been made in this regard: a) It was found that when the unsaturated long chain fatty acids used are 20 carbons or more, the nanolipid vesicles form spherical structures with sub-compartments similar to those seen in a sponge.
These structures are stable and it is our belief that antibodies or other ligands would fit ideally in these sub-compartments so that the nanolipid vesicles bind to specific epitopes or receptors at the target cell surface. b) When unsaturated long chain fatty acids of 16 to 20 carbons are used, the form of the nanolipid vesicles is spherical with a dynamic field of moving autofluorescent particles surrounding the vesicles.
When nitrous oxide is omitted from the process the moving particles surrounding the nanolipid vesicles move erratically and asymmetrical movements are then detected.
It is believed that nitrous oxide is essential in stabilising the moving autofluorescent particles surrounding the nanolipid- vesicles, which is an essential characteristic to efficient compound delivery. 2. Stability:
The nanolipid vesicles appear to remain structurally intact after 24 months at room temperature. Any encapsulated active compounds remain encapsulated during this time. This stability feature is believed to be of substantial significance and one of the contributing factors for the enhancement observed. } 3. Absence of cytotoxicity:
The nanolipid vesicles have no apparent cytotoxicity. When applied : 40 to cells in culture, at applicable concentrations they appear rather to have a beneficial effect on normal cell growth.
4. Mechanism of action: 4.1 Loading efficiency:
The high loading efficiency of nanolipid vesicles has been demonstrated by achieving a high degree of encapsulation of a wide range of active drugs. 4.2 Transport:
The nanolipid vesicles behave as a transport mechanism to carry molecules such as active compounds. 4.3 Release:
It has been shown that the nanolipid vesicles have very high delivery efficiencies. The high delivery efficiency relates to tissue penetration, cell adsorption, internalisation of nanolipid vesicles by cells, parasites and bacteria, intra-cellular stability, and subsequent sub-cellular organelle delivery.
The result of high delivery efficiency is the release of active compounds not only at membrane sites, but also at intracellular sites including the nuclei of viable cells or microorganisms. The result is an enhanced efficacy of said active compound. The nanolipid vesicles and active compound appear to act synergistically in attaining enhanced efficacy. 5. Elasticity:
Confocal laser scanning microscopy (CLSM) shows that the conformation of nanolipid vesicles can be changed while in movement.
When the vesicles move through membranes, the conformation changes so that the intracellular nanolipid vesicles may have other morphological characteristics. :
While moving through membranes the nanolipid vesicles ‘feed’ the 40 membranes with unsaturated long chain fatty acids which in its turn will have a positive effect on membrane bound processes. This process has a positive effect on the metabolism of the cell and thus : the survival of the cells. 6. Dynamic inter-lipid vesicle relationships:
It has been shown that vesicle inter-lipid relationships do exist. The lipid vesicles can interchange the compounds they respectively carry.
They can also combine to resize themselves continuously without detriment to their stability. The inter-lipid relationship is also revealed when moving through the cellular membrane.
These interactive membrane characteristics make the movement of the vesicles through the cells optimal.
Although inter-relationships of the dynamic nanolipid vesicles are continuously present, it has also been shown that the particles are stable in blood and body fluids for up to 5 hours.
Without thereby limiting the scope of the invention some examples will now be described to illustrate the invention. Preparations which do not as such form part of the claimed subject matter of this application, being preparations first disclosed in the applicant's own prior patents referred to above, are first restated.
PREPARATION 1
Preparing an aqueous nitrous oxide solution
A pressure vessel is charged to its operating volume with water at 20°C [ambient temperature]. The vessel is connected to a supply of nitrous oxide via a flow control valve and pressure regulator. The closed vessel is supplied with nitrous oxide at a pressure of 2 bar for a period of 48 hours, it having been determined that at the aforementioned temperature the water is saturated with nitrous oxide over such period of time under the : 40 above-mentioned pressure.
A resultant solution is bottled as stock solution for use in the formulations and applications set out below.
PREPARATION 2
Preparation of nitrous oxide/Vitamin F aqueous emulsion 30g Vitamin F ethyl ester as identified and described above was mixed with 10g Cremophor RH40 (which is the trade name used by BASF for a product which it describes as the reaction product of hydrogenated castor oil with ethylene oxide which product is also known by the INCI name as PEG- n-Hydrogenated Castor Qi), 2,2g methyl paraben, 0,08g butyl hydroxyanisole, 0,23g butyl hydroxytoluene with stirring at 80° C.
Into 942,59 of the stock nitrous oxide solution was dissolved 2,5g sodium propyl paraben and 2,5g Germall 115 [Imidurea] with stirring at room temperature.
The oily composition first described was emulsified into the agueous solution with stirring to constitute a stock nitrous oxide/Vitamin F emulsion. It is herein referred to as “Lindil”, “MZL" or “nanolipid-vesicie” formulation.
PREPARATION 3
Preparation of a non-aqueous solution of nitrous oxide in carrier formulation,
The Manufacturing Process for producing a non-aqueous formulation of an anti-infective agent according to the invention will now be described with reference to the manufacture of a first anti-TB medicament containing
Pyrazinamide as active ingredient and a second anti-TB medicament containing the combination of Rifampicin, Isoniazid and Ethambutol as active ingredients. These products are respectively designated as “Preparation P” and “Preparation RIE” herein.
Preparation P was made up according to the following protocol: 40 Step 1: Weigh off the Pyrazinamide 5,00Kg and reduce the particle size to less than 40um.
Step 2: Weigh off and add together the Poloxyl hydrogenated castor : oil 1,15Kg, Vitamin F ethyl ester 2,35Kg, di-a-Tocopherol 150,09 and Polyethylene glycol 400 1,295Kg into mixing pot 2 and heat to approximately 40°C until all the oil has melted.
Step 3: Gas the oil mixture with nitrous oxide for 3 hours at 2 bar in the stainless steel pressure vessel in the manner described in
Preparation 1 above.
Step 4: Transfer the gased mixture to mixing pot 1 and heat to approximately 70°C .
Step 5: Weigh off and add the Methyl paraben 50,00g and the
Butylated hydroxytoluene 5,00g to mixing pot 1, while continuously mixing ensuring each solid is dissolved before adding the next while still maintaining the temperature at 70°C.
Step 6: Remove from the heat and allow to cool down to approximately 40°C.
Step 7: Add the Pyrazinamide 5,00 Kg stepwise while continuously mixing.
Step 8: Gas the mixture from step 7 with nitrous oxide at 20kPa for minutes with mixing until the mixture has reached room temperature. 30 Preparation RIE was made up according to the following protocol:
Step 1: Weigh off the Rifampicin 1,467Kg, Isoniazid 733,009 and
Ethambutol 2,20Kg and reduce the particle size to less than 40pm. Ensure that the raw material is protected from exposure to light at all times.
Step 2: Weigh off and add together the Poloxyl hydrogenated castor oil 1,33Kg, Vitamin F ethyl ester 3,11Kg and Polyethylene glycol 400 1,30Kg into mixing pot 2 and heat to 40 approximately 40°C until all the oil has melted.
Step 3: Gas the oil mixture with nitrous oxide for 3 hours at 2 bar in the stainless steel pressure vessel in the manner as described : above.
Step4: Transfer to mixing pot 1 and continue to mix.
Step 5: Weigh off and add the Methyl paraben 50,00g, Ascorbyl palmitate 10,00g and the Butylated hydroxytoluene 5,00g to miXing pot 1, while continuously mixing ensuring each solid is dissolved before adding the next.
Step 6: Remove from the heat and allow to cool down to approximately 40°C.
Step 7: Check the pH and add Potassium hydroxide while continuously mixing until the pH reads 7.
Step 8: Add the Rifampicin 1,467Kg, Isoniazid 733,00g and
Ethambutol 2,20Kg, respectively, each stepwise allowing mixing after each addition.
Step 9: Gas with nitrous oxide at 20kPa for 30 minutes with mixing until the mixture has reached room temperature.
The Preparation P and Preparation RIE formulations were encapsulated in soft gel capsules in the manner well known in the pharmaceutical trade as oral capsules for use as described below.
EXAMPLE 1
ENHANCEMENT OF ANTI-BACTERIAL ACTION
This example pertains to the enhancement of current treatment modalities of infectious bacterial diseases.
The increased efficacy of antibiotics carried by nanolipid-vesicle in the treatment of bacterial infectious diseases was demonstrated by: (a) and (b) Bacterial culture studies (Bactec studies and confocal laser 40 scanning microscopy CLSM); (c) Infection studies involving live confocal laser scanning microscopy (CLSM) studies; and
(d) Zone of Inhibition studies according to the USP XXIII zone inhibition method.
The following organisms considered to be representative and hence demonstrative albeit not exhaustive of the range of organisms to which the invention relates, were used in the above studies to confirm the invention:
Mycobatteria Tuberculosis (ref strain H37RV)
Mycobacteria Tuberculosis (MDR strains V79 & V25)
Bacillus of Calmette and Guerin (BCG)
E Coli
S Aureus
P Aeruginosa
B.Cereus
A. Niger
C. Albicans
The anti-infective agents in the form of anti-bacterials used in these studies, and again considered to be representative and illustrative of the wide application of the invention, albeit not exhaustive, were Rifampicin,
Ethambutol, Izoniazid, Pyrazinimide and Povidone-iodine, Cloxacillin,
Erythromycin E, Ciprofloxacin, Co-trimoxazole (Sulfamethoxazole and
Trimethoprim combination) and Itraconazole. ~ As will appear from the results discussed below the tests conducted on formulations involving the association of the active ingredient with the carrier prepared as set out in Preparation 2 above, showed a 10 to 40-fold enhancement of the efficacy of selected anti-infective agents compared to conventional formulations thereof, oe A. Bacterial culture studies: (a) The effect of the nanolipid vesicle encapsulation on the action of known anti-mycobacterials in BACTEC determinations. (i) General Methodology of Collection and cultivation of
Samples and Evaluation 40
Clinical isolates of M.tuberculosis banked at the Medical School at
Tygerberg Hospital were cultured on L-J slant cultures and used for
BACTEC analysis. Drug sensitivity determinations in respect of the strains were done. M.tuberculosis strains were selected from a bank of 1800 clinical isolates genotyped according to their IS6110 insertion sequence profiles. The insertion sequence ranges from 1 to 23 copies per strain. These strains have been clustered into families according to their genetic patterns and represent recent transmission clusters because of their most frequent appearance in the community. These strains may also represent more virulent strains although virulence factors in M.Tb. have not yet been clarified.
The mycobacterial strains were carefully selected according to their genetic and epidemiological type. Multi. drug resistant (MDR) strains were selected over a wide range from mildly resistant to highly resistant for Isoniazid, Rifampicin, Ethambutol and Pyrazinamide.
Clinical and laboratory strains of M.tuberculosis were cultured in a medium enriched with ADC enrichment medium with continuous stirring to ensure homogenous bacterial distribution and uniform aeration as described by Middlebrook, G. (1977) in “Automatable radiometric detection in growth of mycobacterium tuberculosis in selective media.” Ann. Rev. Respir. Dis. 115:1066-1069. Under these conditions, cultures grow reproducibly (<1.0% difference).
This technique was established in the Medical Biochemistry laboratory at Tygerberg Hospital.
At a culture density of approximately A600nm=0.16 (1x
McFarland), (Siddiqui, S. H. (1995). BACTEC 460 MTB system.
Product and procedure manual.) M.Tb. strain cultures were inoculated into BACTEC vials. Cultures in BACTEC were grown until a growth index (GI) of 500(%50) was reached. This culture was used as starter culture for BACTEC evaluation of carrier encapsulated antimycobacterial drugs. BACTEC growth of cultures was monitored over a period of 6-10 days and the AGI value for every 24-hour doubling period determined. Every series of experiments were repeated at least 4 times to allow for accurate statistical analyses. Controls, with no drugs, were brought to the same concentrations. Sterility of mycobacterial cultures were monitored by Ziehl-Nielsen staining. 40 All experiments with infectious material should be carried out in a category 3 bio-safety laboratory. All experiments should be carried out in such a way as to ensure maximum safety for all other laboratory co-workers. (ii) Evaluation in respect of Rifampicin
Lindil, also referred to as the nanolipid vesicle formulation was prepared as described in Preparation 2 above and Rifampicin dissolved at a concentration of 80 micrograms per ml, was used in an initial evaluation of the effect of the preparation on
M.tuberculosis cultures in BACTEC. This Lindil/Rif preparation was sterilized by filtration through 0.45 micron filters so as not to give background contamination by other bacteria.
M.tuberculosis Rifampicin resistant patient isolates were acquired from the South African Institute for Medical Research (SAIMR).
Strains TV25 and TV79 were acquired from the strain bank at
Tygerberg Hospital. Both were determined to be resistant to
Rifampicin, Isoniazid an also streptomycin. The catalase activity of
TV79 was found to be negative and that of TV25 to be S5mM. :
Rifampicin was made up in 50% ethanol at a concentration of - 10pg/ml. Eight yl were added to 1ml Lindil to give a concentration of 80ug/mi Lindil. Of this, 0.1 mi was added to a BACTEC vial to give a final concentration of 2pug/ml Rifampicin in Lindil. This is the cut-off value at which M.tuberculosis strains are evaluated for drug resistance or drug sensitivity for Rifampicin.
Results: It was found that Rifampicin in Lindil kills drug sensitive strains of M.tuberculosis to a much greater extent than Rifampicin alone at concentrations below 2ug/ml. Microscopy illustrated delivery of Rifampicin by Lindil into the interior of the bacillus, and these results show that the Rifampicin does not stay encapsulated in the bacillus, but is released from the nanolipid vesicle to the i bacilli internal environment for biological activity. Lindil alone has no bactericidal effect at the concentration employed in this determination.
It was further found that the Rifampicin resistant strain used displayed increased Rifampicin sensitivity when Rifampicin is : 40 delivered to the bacilli via Lindil.
These results were considered to be very important. It has now been shown that Lindil by itself has anti-mycobacterial activity. The observation that Lindil may have an effect on M. Tb. alone could only be extrapolated from results over the first 24 hours. It would appear that only after a 1:128 dilution of Lindil, growth of M.Tb. is the same as for the untreated control. Co
It was further found that the application of Lindil/Rifampicin combinations to the Rifampicin resistant strain TV79 resulted in an : inhibition of the same order as was observed with the Rifampicin resistant patient isolates which displayed inhibition by
Lindil/Rifampicin at a concentration of 0.5pg /mi Lindil. (iii) Evaluation in respect of Isoniazid “INH”
A*quantity of MZL as prepared in Preparation 2 was filter sterilized through a 0.22uM syringe filter (Millipore). MZL was diluted in the ratios of 1:2, 1:8, and 1:32. These dilutions ranged from an inhibitory effect on the viability of M.Tb. to slight inhibition on the viability of M.Tb.. These effects were observed with serial dilutions of M.Tb. in BACTEC.
INH was reconstituted with MZL dilutions in two ways: First, dilutions of MZL were made as described before, and INH was added to the dilutions to give a final concentration of 0.1ug INH/mI
MZL per BACTEC vial (4ml content). Secondly, INH was reconstituted with undiluted MZL to give a final concentration of 0.1
Hg INH per ml MZL. The viability of drug resistant strain TV25 was evaluated in the presence of the INH/MZL combinations in BACTEC.
The Delta Growth Index (dGI) was calculated for each combination. . The dGI is an indicator of Mycobacterial growth over a period of em time and is determined: dGI = GI (day+1) - GI (day). :
Results
The results are set out in Figure 1. It shows that after 6 days incubation in BACTEC (dG5), the dGI for M.Tb. strain TV25 was still below 10 in the presence of MZL and INH reconstituted prior to 1:2 dilution, whereas the sample subjected to the formulation in which 40 the 1:2 dilution of MZL was made prior to INH dilution already showed strong positive growth with a dGI = 28.
TABLE 1
H37RVv reference strain treated with Ethambutol. Consecutive treatment of H37Rv with MZL carrier.
I A FF MH A
OO
EtMzLapg/mi | 8 4 3 a 3a 3 33
Enzo ugimi | 64 3 4 4.6 6 eo 8
EthMZLipg/m | 6 5 4 10 1323 31 4359
EtMZL Spg/mi | 5 8 5 10 20/739 6g 109 “159
EthMZL 125 pg/ml | 8 4 4 8 19.46 89 142] 10
Ethsug/m | 15 21 29 48 e6}100 138 162-7209
Eth.0625pg/mi ~~ [ 200 45 07 211] 338 630 840 999 999
Eth 03125 pg/ml [ 20] 43 of] 218 3777665 909 ‘999-999 a SS pL heme
Control+MzL [7] § & 21 44708 186 280] 415
This represented an increased inhibition of 78% compared to the effect of MZL dilution prior to INH addition. The effect of MZL alone was 50% relative to the control for strain TV25. Relative to the control, the effect of MZL combined with INH followed by dilution, was 91%. This gave an additional effectiveness of 41.5% of INH (INH alone showed no effect) in the presence of MZL. (iv) Evaluation in respect of Ethambutol
Ethambutol was prepared in sterile deionized water and dissolved in
MZL at appropriate concentrations and the mixtures then sonicated in a cup-horn sonicator for one minute at frequency setting 7. It was brought into contact with a culture of M.tuberculosis H37Rv known to be resistant to Ethambutol. GI was determined every 24 hours + one hour. The observations are recorded in Table 1.
Calculations:
Figures in the highlighted column (6) were used to calculate the effect of Ethambutol on mycobacterial growth in the absence of
MZL. At this point the untreated TB control is GI=540. This is also - the point where the TB growth becomes stationary (decline in growth). All GI values in this column were calculated relative to the control value of 415 to give % inhibition of growth. Column (9) shows the MZL treated control at approximately GI=415. All GI values in this column (Ethambutol in the presence of MZL) were calculated relative to the control value of 415 to give % inhibition of growth. The untreated control value was normalized to 415 to make results comparable. The results of the calculations are set out in
Table 2.
Table 2
Results:
The results show that the MIC for Ethambutol in M.tuberculosis
H37Rv strain is around 1.0 pg/ml. Results clearly show that from 0.125ug/m! Ethambutol, MZL presence still maintains a strong inhibitory effect on mycobacterial growth compared to MZL untreated bacteria whereas there was no growth inhibition. In fact, a slight stimulation of growth (negative values) is observed. This is usually observed with very low antibiotic manipulations. At the higher Ethambutol concentrations (0.25-1.0ug/ml) there does not appear to be much difference in growth inhibition between MZL treated and untreated. The very high concentrations appear to have a better effect in the untreated M.Tb. This effect could be a dose response because of the very high presence of Ethambutol at the 40 high concentrations. In the MZL treated experiments it appears as though MZL captures Ethambutol in its structure making less
Ethambutol freely available for diffusion over the mycobacterial : membrane, However as the concentrations become lower it appears that MZL gives a steady delivery of Ethambuto! to the
M.Tb. with the result that inhibition is steadily maintained (approx 50% inhibition over the range of 0.03125upg/ml-0.125ug/ml).
From these results it appears that MZL maintains steady state delivery of Ethambutol to the M.Tb. over the spectrum of concentrations used and this effect is most prominent in the low concentration range of MZL that is the concentration range significant for therapeutic efficacy. (b) The effect of nanolipid-vesicle encapsulation of the antibiotic
Pyrazinamide on the resistance of BCG (Bacillus of Calmette and Guerin) to Pyrazinamide:
The encapsulation of antibiotics Izoniazid, Ethambutol and
Rifampicin into the nanolipid vesicles formulation of Preparation 2 described above resulted in a product suitable for use in the inhibition of Mycobacterium Tuberculosis in bacterial isolates from patients infected with both drug-sensitive and multidrug resistant strains. The results were obtained with the Bactec system, with no human cell involvement.
The significance of the following result stems from the fact that the
BCG vaccine is extensively used for vaccination against infection by - Mycobacterium Tuberculosis (M.Tb.). BCG vaccine is classified as a non-pathogenic mycobacterial strain and is therefore a widely used investigative model of infection by (M.Th.). All BCG strains are resistant to Pyrazinamide (see Morbidity and Mortality Weekly
Report; 1996, vol 45, No RR-4). The effect of encapsulation of this antibiotic by nanolipid vesicles according to the invention and its delivery in that form to BCG was investigated.
In this investigation which was performed by confocal laser scanning microscopy (CLSM), use was made of a live/dead fluorescent stain known as Baclight. It stains live bacteria green and : dead bacteria red. General viability of the BCG's was determined by : 40 the green/red ratio of the bacteria. The effect of equal amounts and concentrations of free and nanolipid-vesicle encapsulated
Pyrazinamide on BCG viability was investigated.
Bacterial viability: The general viability of the BCG ‘s before any : addition of antibiotics was between 85 - 95%. The BCG-viability after a two-hour incubation of the applicable dosage of free
Pyrazinamide was 68 -72%.
Bacterial growth characteristics: BCG generally grows in clumps. Incubation with free Pyrazinamide resulted in the appearance of single live bacteria with a few granuloma-type clumps, which gradually secrete single live bacteria. The single live bacteria were mobile. Encapsulation of Pyrazinamide in nanolipid- vesicles led to a 65-75% decrease in BCG viability within a two-hour incubation. No moving BCG was observed.
Accordingly, BCG prelabelled with live/dead Baclight bacterial stain and then treated with nanolipid-vesicle encapsulated Pyrazinamide was observed by confocal laser scanning microscopy. It was found that, after an hour, most of the bacteria were labelled red, and were therefore dead. No granuloma-type clumps or single bacteria were observed. Such clumps and single bacteria, all coloured green, were seen in the control in which the same quantity of Pyrazinamide in water alone was brought into contact with BCG also prelabelled with live/dead bacterial stain.
The study thus yielded the most surprising result that bacterial resistance to Pyrazinamide may be overcome by encapsulation of the antibiotic into the nanolipid vesicles composition of Preparation 2. (c) Infection studies (Live confocal laser scanning microscopy studies)
In this study the aim was to determine whether encapsulation of an antibiotic by nanolipid vesicles gives rise to a product by which one could overcome resistance of intracellular bacteria, using infection of human macrophages by BCG in culture as a cell model.
The THP1 macrophage cell line (ATCC) was used for the infection 40 study. RPMI 1640 with L glutamine cell culture medium, Foetal
Bovine Serum and phosphate buffered solution (Gibco BRL), were used for cell growth according to general cell culture methods.
THP1 macrophage cells were cultured and infected with pre-treated : labelled BCG bacteria. Treatment consisted of equal concentrations namely 0.075 pg/ml of free and nanolipid-vesicle encapsulated
Pyrazinamide. CLSM was used to determine infection by and survival of the bacteria.
The viability of BCG's after infection in ‘macrophages reflects that
BCG's inside macrophages treated with nanolipid-vesicle associated
Pyrazinamide is effectively killed by the antibiotic Pyrazinamide, even though the bacteria are generally recognised to be resistant to the antibiotic used. (d) Zone of Inhibition Studies: (i) Enhancement of Povidone iodide against two bacterial organisms as evidenced by zone of inhibition studies.
Inhibition of bacterial growth of two types of bacteria by the active ingredient known as Povidone iodine in formulated form with the nanolipid vesicles of Preparation 2, and so used at a concentration of 6.30g Povidone iodine equivalent to 0.75g available Iodine in 100g of product, was compared with the effect of the same amount and concentration of the free active ingredient. The bacteria were S. Aureus and
P.Aeruginosa. The control used was saline. "The results.obtained in the study are graphically represented in the graph which is Figure 2 hereto. It is clear that inhibition ~ of bacterial growth in both types of bacteria is dramatically increased when the’ active is associated with the nanolipid vesicles. (in Enhancement of five anti-infective agents against five different bacterial organisms
Ll
Five commercially available antibacterial compositions containing the active ingredients set out in Table 3 below were compared in zone inhibition studies with saline as control with compositions of the same active ingredients made up in a carrier according to the invention. These : 40 are designated “MZL" formulations in the case of aqueous made according to preparation Z above and “MZLA” formulations in the case of non- aqueous formulations prepared according to Preparation 3 above. This convention is also followed in other examples below as opposed to the commercial formulations (COM) of particular active agents. The compared : formulations were diluted where necessary to achieve the same concentrations. )
It is evident from the results set out below that the organisms were more sensitive to the active agents when encountered in the carrier formulation according to the invention.
TABLE 3
ZONE OF INHIBITION STUDY: FIVE COMMERCIAL ANTI-INFECTIVE
FORMULATIONS AGAINST FORMULATIONS ACCORDING TO THE
ACTIVE MZLA/ | Dose
AGENT Com | mg/ - 0
Smi | 3 5 4 C 5
Q 5 [J] 2 5 5 @ 3 o |S < < O O Z < wn ol an) Li < J (Cloxacilin___[MzL [125 [30.74 23.96]
Cloxacilin___ | COM [125 [29.45(19.86
Erythromycin |MzL 250 [26.7 | [29.89
Erythromycin [COM [250 [25.84 | [27.78] | [
Ciprofloxacin [MzL [250 [33.05 | [35.78
Ciprofloxacin | COM |250 [30.44 | | "1334
Cotrimoxazole [MZL [240 [13.95 | [24.64]
Cotrimoxazole [COM [240 [11 | | 122.83
Itraconazole |MZLA[50 | [| | 176.03] 14.28]
Itraconazole [COM [50 | [1 110.21 11.47
Control [| Jo Jo Jo Jo Jo Jo
Example 2
ENHANCEMENT OF ANTI-VIRAL AGENTS
In this study AZT at different dosages was associated with the nanolipid vesicles to test the efficacy of such association on the viral growth in
CD4+ Helper T-cells.
The rationale for this investigation is that AZT is cytotoxic and long-term use is associated with loss of muscle. Other side effects can be nausea, anaemia, white blood cell depression, mouth sores, bone marrow damage, and headaches. It would therefore be desirable from both a side effect and cost perspective to be able to lower the dosage of AZT : 20 administered to an HIV-infected patient, provided that such lowering of dosage does not compromise the effect of the administration. It was thus decided.. to investigate the dose/effect relationship of AZT when formulated with the administration medium of Preparation 2.
Although it was the result the applicant had hoped for, it was nevertheless a surprise to find that these objects may be accomplished by increasing the effective delivery of AZT to HIV-infected cells, thereby maintaining a therapeutic intracellular concentration at lower dosages.
From the observations made it is presently postulated: a) That the AZT-loaded nanolipid vesicles significantly increase the kinetics of intracellular and intranuclear AZT delivery, with the result that AZT therapeutic dosages can be decreased; b) That nanolipid vesicle-associated AZT appears to assume the pharmacokinetics of the vesicles until such time as it is released and;
C) That the optimal loading concentration for AZT-loading into nanolipid vesicles can be determined with regard to the applicable cell types.
The following protocols were followed in this investigation: a) Several cultures of CD4 helper T-cells (CEM-SS cell line; NIH
AIDS Research and Reference Reagent Program) were infected with HIV subtype D viruses at applicable cell seeding densities and viral loads. Cells were maintained in tissue culture under standard culturing conditions. b) The viral load in cultured cells were determined every day for 7 consecutive days after infection by measuring the p24 core antigen of HIV-1 in the supernatant culturing fluid by ELISA. This assay is based on a colour change after addition of substrate that is proportionate to the viral replication in each culture. The colour change is monitored by absorbance spectrophotometry at 450 nm. Negative control absorbance readings were used to calculate the absorbance/cut-off for each culture. c) Determination of the optimal concentration of nanolipid-vesicle containing base formulation was done by cytotoxicity assays and cell growth curves. The cytotoxicity assay used was the standard
MTT assay and spectrophotometry was once again used to . determine cell viability for the CEM-SS cell line. Growth curves were used to determine the optimal concentration of base formulation for human macrophage cells (THP-1 cell line). 40 The results obtained are graphically presented in Figure 3 hereto. It : shows the following:
a) The delivery and transport function of the nanolipid- : vesicles increase the therapeutic efficacy of AZT ten fold at a dilution of 1:512 base formulation, thereby creating the possibility of decreasing the AZT dosage 10 fold, as is shown by the relative effect of 1nM free AZT versus 0.1 nM nanolipid-vesicle formulated AZT. The results clearly show that the addition of 0.1nM free AZT inhibited viral growth and replication by 44% by day 7 and 8, when compared to the control (no AZT added). However, the addition of 0.1nM nanolipid vesicle-associated AZT inhibited viral growth by between 70 - 80% on day 8. This is comparable to the inhibition observed by 1nM free AZT (i.e. 10 times the concentration). Furthermore, addition of 0.1nM nanolipid vesicle-associated AZT showed a continued decrease in viral load over 8 days, whereas the addition of even 10x that amount of free AZT resulted in a decrease in viral load up to day 6, after which the viral growth increased slightly. b) The graphs in Figure 2 show that the association of AZT with nanolipid vesicles changes the pharmacokinetics and possibly the intra-cellular biodistribution of AZT. c) The effective delivery of the basic nanolipid vesicle formulation has been established for CD4 T-cells and macrophages to be a dilution of between 1:512 and 1:1024 of the concentrated unfiltered formulation. Higher content of nanolipid vesicles appears to favour viral growth in the cells. At a dilution of base-formulation (1:256), viral inhibition is optimal at a higher concentration of AZT (0.5 - 1nM).
Note that no correction has been made in the above evaluation for the contribution of the cells itself to the Absorbance/cut-off ratio. It was considered to be negligible (>0.4).
Conclusions: a) The administration medium of Preparation 2 at the correct ) 40 dilution may be used to decrease the effective therapeutic dosage of AZT by as much as 10 fold. It would considerably decrease the cytotoxicity of the AZT treatment. At such low dosages, it may be more attractive to treat expecting mothers for HIV infection, without any long-term side effects on the foetus. b) Optimisation of nanolipid vesicle concentration for AZT-delivery is essential, as unloaded nanolipid vesicles can favour the multiplication of HIV viruses by supplying components for viral membranes synthesis and energy for viral metabolism, as the metabolism of nanolipid vesicle essential fatty acids (EFAs) may increase the energy status of the cell, and therefore also the energy available to the HIV virus for its replication. The nanolipid vesicle concentration must therefore be sufficient to serve only its transport function, without supplying either membrane components or energy for viral multiplication.
The changed pharmacokinetics and intracellular biodistribution of AZT transported by nanolipid vesicles are probably the result of the following two mechanisms: a) the change in environment with regards to charge and hydrophobicity when nanolipid vesicles move from the extracellular to the intracellular environment, and b) the normal cellular pathways of the EFAs, which include its metabolism in the mitochondria. The release of AZT is therefore most probably in the region of the mitochondria.
Example 3
Yeasts and fungi: The enhancement of agents used in the treatment of Infectious Diseases caused by Yeasts and Fungi.
The use of this invention for the enhancement of agents used in the treatment of yeasts and fungi (moulds) was investigated and established by the following studies described in greater detail below, namely:
Comparative culture studies
Infection studies (Live CLSM imaging) :
Zone inhibition. : (a) Comparative culture studies:
Fungi of the mycosis type was grown in culture medium (RPMI 1640 with
L glutamine cell culture medium) at 37°C at 90% humidity, 5% CO for a 40 week. Equal aliquots of grown fungi were exposed to nanolipid vesicles ‘ loaded with a commercially available antifungal agent containing 2%
Miconazole nitrate. Comparison was made with free Miconazole nitrate i.e. the commercially available form of that active ingredient. In both instances the exposure was at a final concentration of 0.4% over similar time periods (30 minutes to 18 days), using a single initial dosage.
Results:
The nanolipid-vesicle delivery system can be used for the efficient delivery of antifungal agents to fungi.
Miconazole nitrate association with nanolipid vesicles, but not free
Miconazole nitrate caused a fast and unexpectedly dramatic decrease of the fungi as illustrated in Table 4.
TABLE 4
VIABILITY OF FUNGI AGAINST TIME ELAPSED AFTER SINGLE
EXPOSURE TO MICONAZOLE NITRATE
Nanolipid-vesicle Free
Time encapsulated Miconazole| Miconazole (b) Infection studies:
Two equal aliquots of melanoma cells (UCT Mel 1 cell line) were incubated for 4 hours with fungi and 0.2% of either free Miconazole
B nitrate or Miconazole nitrate formulated with the administration oo 25 medium of Preparation 2 in order to test the effect of the formulation in terms of the invention on the efficacy of fungal treatment of human cells.
The viability of both human melanoma and human macrophages was found to decline dramatically in the presence of free Miconazole nitrate but not when the Miconazole is encapsulated in nanolipid vesicles. The result is graphically presented in Figure 4 hereto.
Figure 4 shows the viability of both the human melanoma and fungi 4 hours after the addition of the therapeutic agents in a petri dish.
© 76 '
Using a macrophage cell line, the same result was obtained. .
Melanoma cells were healthy after 4 hours incubation with nanolipid- vesicle encapsulated Miconazole nitrate and no fungi was present. In the presence of free Miconazole nitrate, cells were no longer attached to the petri dish and fungi were still present in large numbers. (c) Zone of inhibition studies:
Zone of inhibition studies on yeasts and moulds namely C. Albicans, ~ I. Mentagrophytes and E. Flocossum were also carried out.
Inhibition of yeast and mould growth by the active ingredient
Miconazole nitrate in association with nanolipid vesicles was observed. The control used was saline.
The result of this study is reflected in Figure 5 hereto
Conclusion:
It is quite clear from the results presented in Figure 5 that the active
Miconazole nitrate in association with the nanolipid vesicles inhibits the growth of both yeasts and moulds and does so to a greatly enhanced extent.
Example 4
Parisitology: The treatment of Infectious Diseases caused by parasites:
The effect of free and non-aqueous nanolipid formulated chloroquin made according to the process described in Preparation 3 against a resistant
Falciparum strain (the reference strain W2 for drug resistant malaria) was preliminarily determined in the conventional manner. The strain is known to have a 50% Inhibition concentration value (ICsy) of between 200-300 nmolar Chloroquine. The determined ICsy value for nanolipid formulated
Chloroquine was about one tenth of the value for free chloroquine, namely 25-30 nmolar. This most surprising result holds substantial promise for further research as its utilisation in practice means that malaria would be capable of being treated with greatly reduced : cytotoxicity and resulting lower incidence of side effects. In addition drug 40 cost will also be lower.
Approach and general Method
The specific parasite investigated was the reference drug resistant strain : 5 W2 of the species Plasmodium Falciparum. Plasmodium Falciparum is the most commonly occurring as well as the most virulent malaria parasite . currently known in man.
The system used in this investigation aims to mimic the live situation as closely as possible. For that reason, the parasites were infected into fresh primary erythrocytes isolated from O+ or A+ blood donors.
Furthermore, human serum prepared from the same donors was used as an adjuvant instead of foetal calf serum. Parasite growth was maintained by the addition of freshly prepared erythrocytes from the same donors.
The growth of the parasites was determined by visualization of the parasite DNA on thin smears of the infected cultures. Since mature erythrocytes contain no nucleus, and therefore no DNA, the only DNA present was of parasitic origin. Only intracellular parasites were included in determining the percentage parasitaemia, as extracellular parasites are no longer viable.
Protocol: :
The protocol was typical for work of this nature and included the following steps as will be readily apparent to those skilled in the art.
A. Culturing of malaria parasites: 1. Preparation of fresh human erythrocytes 2. Preparation of human serum from the same donor. 3. Quality control of human serum. 4, Infection of erythrocyte cultures with parasites. Initial infection load was 0.5% parasitaemia. 5. Maintenance of parasite blood cultures 6. The parasite percentage in the blood cultures was determined after 36 or 48 hours, depending on the level of infection of the freshly added erythrocytes. . 40
B Basic toxicology:
Determination of possible toxic effect of nanolipid formulations on erythrocytes and parasite growth.
The following nanolipid formulation concentrations were investigated: 0.1:1500, 1:1000; 1:750; 1:500; 1:250; 1:100; undiluted. : -C Loading of nanolipid formulation with chloroquine:
A stock solution of 10mM chloroquine solution in a 1:250 dilution of nanolipid formulation was made by vortexing and sonication. All concurrent dilutions were from this stock.
D Drug delivery by MZL nanolipid formulations: 1. Penetrance of nanolipid formulations in red blood cells was determined by microscopic visualization, as were the penetrance of chloroquine-carrying nanolipid formulations. 2. The drug concentration series used centred around the known 1C50 concentration of chloroquine in the W2 strain. 3. Typically 48-well plates or 96-well plates were used. 200ul or 100ul total culture volumes were used respectively, of which 90% of the volume was infected erythrocyte culture. 10% volume was used for the treatment, be it chloroquine in ‘Nanolipid formulation, chloroquine in water, or for the controls 1:250 pure Nanolipid formulation, pure culturing media or water only. 4, All series were in duplicate.
E Visualization of intracellular parasites:
Parasitic DNA was visualised by Giemsa staining of thin smears.
Ethidium bromide or acridine orange may be used for fluorescent staining.
F % Parasitaemia:
The % infection after applicable incubation periods was determined as follows:
: Total parasite count per 10 microscopic fields ee ee emma 100%
Total cell count per 10 microscopic fields
G Quality assurance of counting:
All counts of the first series were undertaken by two scientists. The results correlated very well. The second series was spot-checked by a second scientist, especially around crucial concentrations. Once again no significant deviations were found between the two sets of results.
Results:
The counts of the cultures are reflected in the table 5 below:
TABLE 5 lee 1 leo [|]
Chloroquin e % Parasit on field [cells [sites |MZL field cells [sites [|Parasit 2.88] 60] 600] 14] 2.33] sonM | 90] 900] 13] 1.43] 113] 1110] - 30] 2.7] 750M | 54) 540 5] 0.9] 129] 1290] 43] 3.33]
W2= Chloroquine resistant strain internationally recognized and used.
CLQL = Chloroquine in 1:250 dilution MZL nanolipid carrier; concentrations of chloroquine as indicated.
CLQ= Chloroquine in medium at the specified concentrations.
Resistant strains become sensitive only at very high Chloroquine concentrations.
Association of chloroquine with nanolipid formulation results in a similar susceptibility as sensitive strains.
Statistical analysis of the results was by Chi-square analysis between the two sets of data. A combination of the 3 repeats of the two sets of data gives a Chi-square value of 7.6. According to the probability tables, the difference between pure chloroquine and MZL-associated chloroquine is highly significant, with only a 0.0001 probability that the difference observed between the two treatments is due to chance.
Conclusions: 1. The association of chloroquine with MZL nanolipid formulation significantly decreases the ICs of chloroquine (by' 6x to 10x). 2. Primary human cells show high tolerance for the MZL nanolipid formulation, with cytotoxicity only observed at high extremely high concentrations. 3. MZL formulations may be used in the prophylaxis of drug resistant malaria.
Example 5
Comparative release properties as determined by Membrane Diffusion of
Anti-infective agents formulated in accordance with the present invention and commercially available formulations of the same anti-infective agents. 1. OBJECTIVE
The scope of this study was to establish whether the Test Anti-infectives
Acyclovir and Miconazole Nitrate are released from the dosage form of the invention at a satisfactorily rate and extent in comparison to the commercially available Comparators.
The applicability of the test method for release out of the dosage forms was confirmed by Handbook of Dissolution Testing: Dissolution Testing of
Transdermal Delivery Systems, page 61. The small receptor volume to be used, in this case 12 m{, is confirmed in the same reference on page 63, which refers to 5 ~ 25 md. 2. METHOD ~The in vitro release from the dosage forms was determined by a Hanson
Model 57-6M, Manual Start-Up, Diffusion Cell Test System bought from
Hanson Research with the following main parts:
CELL DRIVE CONTROL
6-CELL DRIVE WITH CELLS
VERTICAL CELLS
3. PARTS NEEDED 1. Diffusion cell assembly, including donor top and receptor chamber (set of 6). The donor top includes a drug dosage wafer (Teflon washer), an acrylic top plate, and a clamp to connect top to bottom. 2. Pig skin used within 24 hours from being slaughtered kept in
Ringer Solution between 2°C - 8°C. 3. Davies Gold Series Dermatone, Simplex GS 102. 4. Application squeegee and tweezers. 5. Drug dosage form. 6. Absorbent paper towels and tissues. 4, TECHNIQUE : 1. Obtain skin from pig heads (jawbone skin). Use Dermatome 40 according to the Operation standard operating procedure for the Dermatone, setting it to size the skin to a thickness of
0.33mm. The diameter of the skin should be in excess of the drug dosage wafer. 2. Prepare receptor chamber of diffusion cells with slight overflow of medium (pH 5 buffer with glacial acetic acid for the Test Product Acyclovir and 6.8 phosphate buffer for the test product Miconazole) with temperature controlled at 32°C. 3. Prepare each piece of skin with the relevant products one at a - time as follows: - 3.1. Lift skin with tweezers, place on tissue and blot excess of solution, invert and blot. 3.2. Place skin in centered position on drug dosage wafer. 3.3. Place relevant products on top of skin in dosage wafer cavity - 0.5 ml by means of a Gilman pipette - weighed and averaged to obtain dosage applied. 3.4. Use squeegee to carefully smooth product over membrane, filling entire cavity. 3.5. Wipe excess dosage water with squeegee. 3.6. Lift loaded dosage wafer with skin and place on top of receptor cell with skin side towards cell medium.
Exclude bubbles during process. Place on top of donor cell assembly, pressing down with finger, squeezing out bubbles between top plate and dosage form. Apply clamp to lock down top donor and bottom receptor halves of diffusion cell. 5. OPERATION OF APPARATUS
The apparatus must be set to 150 rpm. Samples of 150u! are withdrawn with a micropipette at 2’, 5’, 8 and 10’ and 15 minutes. The samples after being withdrawn are analysed for Acyclovir and Miconazole Nitrate respectively by means of HPLC according to the parameters set out in
Table 6 below.
. Table 6 ee Acyclovir Miconazole Nitrate
Injection volume 250mm x 4.6mm 250mm x 4.6mm pH 3.5 30% H>0 +1% GAA
Cellsused ~~ [3 (ifor Comparator) |6
EERE release determined
Min 6. RESULTS
The release experiment was performed in the number of cells indicated above for each product and the mean release is reported for each analysis point. The results are tabulated and graphically presented. The results as a percentage of the active released per label claim per cell at the different time intervals is also tabulated.
In Table 7 below is shown a summary of the release rate and percentage release per label claim for the products determined according to calculations, reporting the mean values of the utilised number of cells of each product after the effluxion of the time indicated above.
Table 7
Table indicating release rates and percentage release per label claim for product tested. /product (ug/cm?/h) label claim
Nitrate MZL
Nitrate
7. CALCULATIONS
The Release Rate was calculated as follows: 7.1. pg Active Released at time (min.) = A sam x Mass _Std x Vol Receptor x Mass of Active Applied for Z cells x C
A std x Vol Std x Label Claim x Mass of Product Applied for 1 cell x Z x 100
WHERE:
A sam = Area of peak sample solution
A std = Area of peak of standard solution
Mass std = Mass of standard taken to prepare the standard solution expressed in pg
Vol Std = Volume to which the standard solution is ~ made up, expressed in m{
Label Claim = Amount of active present per 100g of product
Mass of Product
Applied for 1 cell = Specific amount of product applied for a specific cell
Mass of Active
Applied for Z cells = Amount of active applied in total for all Z cells utilised per one study
Cc = potency of the standard, expressed as a percentage 7.2. Accumulative Dose (ug) released /square cm at time (min) = ug Active Released - (Surface Area of Exposed Skin) = ug Active Released : 1.767 cm? 7.3. Release Rate 40 : = Accumulative Dose (ug) released / square cm
Time (hours)
7.4. Percentage of Active Released at time (min.) = Lg Active Released x 100
Hg Active Applied 8. CONCLUSION
From the aforegoing test it was concluded that the formulation according to the invention (a) releases Acyclovir 1.28 faster than the Comparator Acyclovir formulation at 15 minutes, and continues to release higher quantities throughout the duration of the test; (b) releases Miconazole Nitrate 3.51 times faster than the commercial
Comparator at 60 minutes.
Example 6
DEMONSTRATION OF THE EQUIVALENT OR IMPROVED
BIOAVAILABILITY OF ANTI-TB DRUGS IN THE FORMULATION
AVAILABLE PRODUCT
1. BACKGROUND:
Anti-tuberculosis treatment presents with two major problems- the development of drug resistance and compliance. The nanolipid based delivery system provides a system for single or combination tuberculosis drug treatment with a significantly increased therapeutic index, using currently prescribed anti-tuberculosis drugs, with a resultant decrease in the development of drug resistance. The delivery system contains the same therapeutic moieties but differs in chemical form, and dosage of those moieties and can therefore regarded as a pharmaceutical alternative. Furthermore, the higher therapeutic index of the drug facilitates lower dosage, which limits the side effects, which may in its turn be expected to improve compliance. Using this delivery system, delivery of the drugs may also be expanded to tissues usually not easily reachable by current therapeutic regimes.
The formulated delivery system contains components that have been recognized as pharmaceutically safe. The public health authority of South
Africa in concert with many other health authorities, advise the same 40 actives as used in this investigation as initial treatment regime for all tuberculosis patients. This protocol describes the delivery of the prescribed anti-TB drugs in 4 single daily doses by way of the delivery system at a reduced dosage level to 1 healthy volunteer. :
In an open crossover design, pharmacokinetic parameters of the four drugs delivered by the test formulations in reduced doses were compared to those achieved when the same drugs were administered in the reference formulations of established quality and in the standard treatment doses. The volunteer was monitored daily during the study.
The protocol below describes the dosage level, the specific drug, the time period of the study, the parameters investigated and the combinations of drugs used. 2. STUDY OBJECTIVES
Primary Objectives
The first primary objective of this investigation was to determine the bioavailability of generally used anti tuberculosis treatment agents, i.e.
Rifampicin (R), Izoniazid (H), Ethambutol (E) and Pyrazinamide (2), each packaged into the MZL drug delivery system in the form of the capsules produced in the manner as described in Preparation 3 above.
Secondly, it was to determine changes in patient global assessment, i.e. significant change from baseline of the following pharmacokinetic parameters: } ~~ a) peak plasma concentration (Cmax), b) the time needed to reach this concentration (Tmax),
Cc) exposure (the area under the plasma curve (AUC 0-9 : hours), and d) coverage.
The pharmacokinetic results were compared with those of reference formulations. The packaged drugs were administered at an equal or a decreased dosage of that in the commercially available combination antituberculosis drugs. 2.2 Secondary objectives
The secondary objectives of the investigation were 40 firstly, to determine whether bioequivalence exists for drugs packaged into the delivery system by comparison to reference agents;
. secondly, to determine whether there are changes in the status of side effects caused by the actives; thirdly, to determine the relative safety levels of the comparative products; fourthly, to determine possible partitioning of the MZL nanolipid delivered drugs to cells and possible cytotoxicity as a result; and finally, to note the possible advantages to the volunteer's well-being (i.e. malaise, bone ache, nausea etc) when using the delivery system of the invention for the administration of anti-tuberculosis drugs. 3. STUDY DESIGN
The treatment was based on the Standard Treatment Guidelines and
Essential Drugs List (1998). The study design was an open crossover bioavailability design of tuberculosis drugs [Rifampicin (R), Izoniazid (H);
Ethambutol(E) and Pyrazinamide(Z)] delivered by a formulated drug delivery system. Bioavailability is understood to be the rate and extent to which the active substance or therapeutic moiety is absorbed and delivered from a pharmaceutical form a) into the general circulation and b) becomes available at the site of action.
As in other bioavailability studies, the kinetics of the therapeutic moiety in the general circulation was monitored in this study.
The study was conducted over two periods of 4 days each, interrupted by a two week wash out period. During the last day (day 4) of each period, blood samples will be taken at the times specified below to determine several pharmacokinetic parameters. Blood samples (10ml each) were taken at the following intervals after administration of the drugs: 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 9 hours. 3.1 Rifampicin: 40 The volunteer received the currently commercially available prescribed
Rifampicin, namely Rifampin, treatment for 4 consecutive days, followed by a wash out period of 2 weeks. Rifampin contains Rifampicin as active ingredient. The volunteer then received pure Rifampicin packaged into the nanolipid delivery system of the invention as described above at two thirds of the prescribed dosage, again for 4 consecutive days. This nanolipid formulation of Rifampicin is herein also referred to as
Rifemzaloid. The volunteer took the medication in the morning before a meal with 200ml of tea, as food has been shown to influence absorption.
Meals were standardized and supplied a couple of hours after first administration of the medication. 3.2 Combination Drugs:
The volunteer started with two third dosage of all four drugs packaged into the nanolipid delivery system of the invention, followed by the same scenario with the commercially available treatment regime, namely
Rifafour, after a two week wash out period. The volunteer took the medication in the morning before a meal with 200ml! of tea, as food has been shown to influence absorption. Meals were standardized and supplied a couple of hours after first administration of the medication. 3.3 General Protocol Requirements: a) The subject volunteered for participation in the study. The volunteer was a Caucasian middle-aged female and was clinically healthy i.e. blood chemistry, full blood count and liver function tests of subjects fell within the normal ranges. The volunteer granted written informed consent before participating in the study. b) All drugs were orally administered in Soft Gel capsule form at applicable doses. The volunteer did not take any other chronic medication during the study.
Cc) The study was single blind for laboratory procedures. Plasma level assays of the actives were performed in the conventional manner. d) Blood and liver function assays were undertaken in the conventional manner. @) The safety of the treatments was assessed according to the ICH
Clinical Trial Guidelines. No serious adverse events (AE) occurred } during the study.
4 TREATMENT REGIME: 4.1 Pharmaceutics ‘The nanolipid delivery system formulated as described above was used as a base for the active drugs used when comparing the pharmaceutical efficacy of drugs delivered by a delivery system with the generally prescribed drugs containing identical actives. 4.2 Dosing:
Rifampicin: :
Commercially available Rifampin tablets (600mg) were taken daily for four consecutive days, followed by sample collection on day 4.
Nanolipid formulated Rifampicin was taken in the same manner but at two thirds of the above dosage, i.e. 400mg Rifampicin encapsulated in the delivery system. Dosing was again followed by a sample collection in order to determine the comparative pharmacodynamic profile of the active.
Combination treatment:
The generally prescribed drug regime, consisting of 5 combination tablets Rifafour RHZE (120 /60 / 300/200 mg) were taken daily for 4 consecutive days, after which blood samples were collected for plasma concentration analysis.
In the nanolipid combination formulation, 5 capsules containing a : two third dosage of each of the actives i.e. RHZE 100/40/200/132mg were taken and analysed in the same manner. 4.3 Study Supplies
The drugs used in the study were packaged into the nanolipid delivery system, manufactured according to Preparation 3 above and labelled in accordance with Good Laboratory and Manufacturing Practice (GLP 40 and GMP) Guidelines for the labelling of study medication as set out in
Table 8 below.
Table 8 4.4 Sample Collection and Preparation
Blood (10ml) was collected at specified times for HPLC determination of the plasma concentrations of Rifampicin. Blood was also collected for liver function determinations and full blood cell counts.
Samples were collected in heparinized tubes and placed immediately on ice. Plasma was extracted by centrifugation within 15 minutes of collection and stored at a minimum of minus 80°C.
Sn UY Prescribed treatment: RHZE combination tablet or +
Dosage’ '©L... ' IRHZE mg/tablet RHZE mg/day |RHZE mg/week
Less than 50.kg™ 7 7+ 1120/60/300/200480/240/1200/800 |2400/1200/6000/4 oretnan SOkG 1: 1120/60/300/200[600/300/1500/10003000/1500/7500/5 “itp Deion Drugs administered by drug delivery systems...
Drtig delivered:treatmentiDrug mg/capsulelDrug mg/day [Drug mg/week
Rifampicinp Rice 1H100mg 400mg |2000mg [oniazid; H/o. © 77 [100mg Doomg [100mg pyrazinamide; Z 00 noPS0mg |1000mg 5000mg
Etfemoutoli £00 = (137mg ___lesomg_______Daoomg
Hindi id Prescribed tFéatment: <RHZE combinationtablet: ver nw
DEsa0e to a i RHZE mo/tablet |RHZE mg/day ___|RHZE mg/week
Fest than 50:KG7 = -4e11 20/60/300/200480/240/1200/800 _|2400/1200/6000/4 more than 50KGY~ 1 11 20/60/300/200]600/300/1500/1000/3000/1500/7500/5
FENN Drugs administered by drug delivery system. ian nL } ro delete oat mentbrug my/capsulebrug mg/day bru mg/week we Rifampicin; Refs 50 100mg [400mg 2000mg
Isoniazid; He F00i100mg 200mg [1000mg
Pyrazinamide;Z-» 250mg 1000mg _________ [5000mg
Etharmbutol:Eiti ni" [132mg 660mg [3300mg
Blood samples were collected and handled in accordance with Good
Clinical Procedures (GCP) Guidelines. 4.5 Plasma concentration determination
The concentrations of Rifampicin(RIF), Izoniazid(INH) and
Pyrazinamide(PZA) and their active metabolites were determined by high performance liquid chromatography after their simultaneous extraction from plasma. The materials used were INH, RIF, PZA and pyrazynoic acid; HPLC - grade acetonitrile, methanol and trifluoroacetic acid (TFA) and C18 Bondelut extraction columns, 200mg, 3 ml 40 microns.
The plasma concentrations of RIF were determined using a mobile phase of 80% acetonitrile in 0.1% trifluoracetic acid. A reversed phase
C8 analytical column (Spherisorb, 250 X 4.6 mm ID, 5um) linked to a
C8 precolumn, with flow rate at 2.0 ml per minute and detection at 270 nm was used.
For the determination of INH and PZA, the mobile phase was 3% acetonitrile in 0.06%. TFA. A reversed phase C8 analytical column (Spherisorb, 150 x 4.6 mm ID, 5um) linked to a C8 pre-column with flow rate at 1.5 ml per minute and detection at 254 nm was used,
Stock standards
A stock standard solution of Rifampicin (0.5mg/ml), PZA(0.5 mg/ml) and INH(0.5 mg/ml) and pyrazynoic acid were prepared (0.5 mg/ml) is prepared in Methanol.
Relative retention times were established by spiking and comparing peak area ratio of RIF.
INH and PZA.
All stock solutions are kept at a minimum of 4°C and protected from light.
Specificity
Analyses of blank samples of the appropriate biological matrix were tested for endogenous interferences in the reference standard region for RIF, INH and PZA.
Calibration graphs (peak areas vs concentration) were constructed for
RIF and INH in the range 0.1-20pg/ml and for PZA in the range 0.1- 60ug/ml. INH, RIF and PZA and pyrazynoic acid analysis were done in triplicate. ‘ 40
Intra- and inter-assay coefficients of variation were determined.
Five replicate samples of four concentrations were run through the procedure with exactly controlled volumes, as described for the extraction of the samples. To verify recovery/quality control, precision and accuracy, the peak areas obtained for the extracted samples were be compared to those of fresh standards of the analytes in mobile phase with respect to the volumes handled during extraction.
C18 Bondelut extraction cartridges were washed sequentially with 2 X 2 ml of methanol, 2 x 2 mi of water and 2ml of 0.05 M potassium phosphate, pH 4.5 (phosphate buffer) prior to application of the sample to the columns.
A 0.5 ml quantity of plasma were thawed and drawn slowly onto the column and allowed to stand for 5 minutes, after which time unbound material were discarded. The columns were washed with 1 ml of phosphate buffer to be discarded, and the drugs eluted with 0.5 mi of acetonitrile, followed by 0.5 ml of methanol with these elutes being pooled. 60 pl of the pooled eluates were injected immediately onto the HPLC column to assay for RIF.
INH, PZA and pyrazynoic acid: 0.5ml of the combined eluates were dried by vacuum centrifugation and taken up in 0.5 ml of 3% acetonitrile in 0.06% TFA. 60ul of this were injected onto the autosampler HPLC to assay for INH and PZA, which were detected together on the same column.
Acceptance criteria:
A validated analytical method meets the following criteria:
Precision and accuracy: The between batch CVs for low, medium and high concentrations should be <15%, and 20% for the LOQ QC.
Sensitivity: The lowest standard should be accepted as the LOQ if the %CV is <20%
Specificity: The responses of interfering peaks at the retention time of the analyte should be less than 20% of the response of an LOQ 40 standard.
Stability: Stock solution stability should meet the criteria specified in : the SOP. 5. RESULTS 5.1 Comparative bioavailability of Rifampicin
The first part of the study concerned only Rifampicin and the nanolipid-formulated Rifamzaloid. The plasma levels determined for the indicated times are reflected in Table 9.
Plasma levels of Rifampicin , MZLA r pe (ug Rif /ml (pg/ml ime(min plasma plasma 0 | oo | oo 30 [| 1031 | 0 60 [| 1293 | 7.46 90 | 11.23 | 10.23 : 330 | 6 | 41
Increased Cmax - The maximum plasma concentration (Cmax) of Rifampicin was determined to be 12.93ug/ml and was reached 60 minutes (Tmax) after oral administration of the active in the nanolipid delivery system. The Cmax obtained for the Rifampin (10.23ug/m!) was ’ reached 90 minutes after administration. The delivery of Rifampicin to the plasma was therefore increased by at least 21% at Tmax by the nanolipid carrier. Furthermore, only two thirds of the normal dosage was taken in the MZL formula. Therefore, the increased delivery of Rifampicin to plasma by the Nanolipid delivery system at Tmax was 181% that of its comparator at equal dosages.
Decreased Tmax
The minimum effective concentration of Rifampicin in plasma is 7pg/ml. It is clear from the results that Rifampicin reaches its effective concentration much quicker when delivered by the
Nanolipid delivery system. This is especially important in the case of unstable drugs such as Rifampicin, as increased gastric exposure may lead to increased loss of activity.
Increased Coverage
Coverage can be regarded as the time period during which the effective concentration is maintained. Figure 6 illustrates that the coverage afforded by using the nanolipid delivery system is increased by 180% (270 minutes vs 150 minutes). It is therefore possible to the increase the time intervals between sequential dosages.
The above parameters reflect the comparative bioavailability dynamics of the Nanolipid delivery system. The total average increase in bioavailability by Nanolipid delivery system was 227%, while using only two thirds of the dosage of the comparator.
Differences in the above pharmacodynamic and pharmacokinetic parameters were statistically significant (see Table 10), with a p- value of 0.0157. The statistical method for analysis used was
Analysis of Variance with a single factor variant.
TABLE 10
SUMMARY OF STATISTICAL ANALYSIS
Groups Count Sum Average Variance
Column 1 11 103.16 9.378182 4.944216
Column 2 11 70.45 6.404545 9.408267
ANOVA
Source of Variation SS df MS F P-value F crit )
Between Groups 48.63382273 1 48.63382 6.77706 0.017005894 4.351250027
Within Groups 143.5248364 20 7.176242
. Figure 6 hereto records the observed bioavailability of Rifampicin in the
MZL formulated Rifamzaloid vs its comparator Rifampin. The comparative daily Rifampicin dosages were 400mg/ day in the case of Rifamzaloid and 600mg/day in the case of Rifampin. 5.2 Bioavailability of Combination Drugs
Similar results were obtained with Isoniazid and
Pyrazinamide. Figure 7 hereto illustrates the enhancement in bioavailability of INH, using the nanolipid delivery system, and Figure 8 that of Pyrazinamide (PZA).
Figure 7 shows the enhanced bioavailability of Izoniazid when encapsulated in the MZL delivery system, even though the daily dosage of the INH in the MZL formula was only two thirds of that of the comparator, Rifafour.
Figure 8 illustrates the enhanced bioavailability of Pyrazinamide in the MZL formulation. Again the daily dosage of the PZA in the MZL formula was only two thirds of the PZA in Rifafour, the comparator. 5.3 Side effects:
No significant side effects were found with the MZL formulated | - liver function analysis. None of the liver enzymes showed levels higher than the normal range. The. S-unconjugated bilirubin, which did show levels elevated above the normal range was nearly back to normal 8 hours after drug administration, and was normal on the following day. 5.4 Volunteer’s assessment:
The only adverse reaction to either of the MZL formulas (Rifampicin or Combination) was nausea, whereas the comparator Rifafour led to serious headache, jitters and } nausea. 5.5 Partitioning of nanolipid formulated Rifampicin: : 40 Between 5-10% of the Rifampicin encapsulated in the nanolipid partitioned to blood cells rather than to plasma.
This partitioning should increase the effective dosage delivered to the cells, but the partitioning is not so high as to be cytotoxic. ,
The study was repeated for Rifampicin and Pyrazinamide with similar results.
Many modifications of the invention may be devised without departing from the spirit and general scope of the invention.
Claims (13)
1. A method of enhancing the action of an anti-infective agent characterised in that the agent is selected from the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1- antagonist antihistamines, comprising the step of formulating the agent with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma- linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and the derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil, with ethylene oxide.
2. A pharmaceutical preparation comprising an anti-infective characterised in that the agent is selected from the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1- antagonist antihistamines, which agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and the derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil, with ethylene oxide.
) 3. The method of claim 1 or the preparation of claim 2 which contains a mixture of esters of the essential fatty acids set out in those . 40 claims and is preferably constituted by the complex known as Vitamin F Ethyl Ester having a typical fatty acid distribution as follows:
08 < Ce: 0 Ci60 : 8,3 %
Cis.0 .
3,5 %
Cis. . 21,7 % Cig2 : 34,8 % Cigg 28,0 % > C18: 1,6 % unknown: 2,1 %
4. The method or the preparation of claim 3 wherein the administration medium further includes eicosapentaenoic acid [C20: 503] and/or decosahexaenoic acid [C22: 6w3] as additional long chain fatty acids and/or the reaction product of hydrogenated castor oil and ethylene oxide known as PEG-n-Hydrogenated Castor Oil.
5. The method of claim 1 or the preparation of claim 2 wherein the carrier is water (preferably deionised water) or any of the pharmaceutically acceptable alcohols, ethers, polymers such as a polyethylene glycol or the like or an oil which is preferably an organic oil which organic oil is further preferably an essential oil based on long chain fatty acids having between 14 and 22 carbon" atoms in the fatty acid and is preferably of natural origin and most preferably a plant oil rich in gamma linolenic acid [GLA].
6. The method of claim 1 or the preparation of claim 2 wherein the anti-infective agent is formulated in a liquid or encapsulated liquid presentation for oral administration or in a nasal or bronchial or pulmonary spray or in the form of an injectable formulation and wherein the formulation incorporate, as part of the administration medium, water or acceptable other liquid into which the nitrous oxide is dissolved, preferably to saturation, and wherein the fatty acid or ester thereof is either dissolved or suspended or emulsified along with the anti-infective agent.
7. The method of claim 1 or the preparation of claim 2 wherein the anti-infective agent is formulated as a topical, buccal or vaginal cream or ointment, or as a suppository, and wherein the ] formulation used in making up such cream, ointment or suppository incorporates, along with the anti-infective agent to be enhanced, a 40 quantity of water or other liquid containing, and preferably : saturated with, nitrous oxide, the long chain fatty acid or ester thereof and the anti-infective agent formulated therewith, and,
optionally further incorporates such additional excipients and
. carriers as are conventionally used in the pharmaceutical trade in making up such dosage forms.
8. The method of claim 1 or the preparation of claim 2 wherein the carrier solvent for the nitrous oxide gas is essentially non-aqueous and composed of at least one fatty acid or ester thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic . acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5w3], decosahexaenoic acid [C22: 6w3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils with ethylene oxide, required to be part of the formulation.
9. The method of claim 1 or the preparation of claim 2 wherein the anti-microbial agent is selected from the groups consisting of : the anti-bacterial agents (including both antibiotics and substances other than antibiotics such as the sulfonamides, the erythromycins and other macrolides, the aminoglycocides, the tetracyclines, the chloramphenicols and the quinolones); the anti-fungal agents; the anti-viral agents (including anti-retroviral agents); the anti-protozoal agents; the tuberculostatics; the anti-leprotics; the germicides; and the spirochaeticides. EE
10. The method of claim 1 or the preparation of claim 2 wherein the anti-infective agent is selected from the group comprising: the anthelmintics, the anti-ectoparasitcides, the anti-bacterial agents (including both antibiotics and antibacterial substances other than antibiotics); the antifungal agents; the anti-viral agents; the anti- RX protozoal agents; the tuberculostatics; the anti-leprotics; the germicides; and the spirochaeticides. : 40
11. The method or the preparation of claim 9 wherein the anti-infective agent comprise at least one tuberculostatic selected from the group consisting of Rifampicin, Izoniazid, Pyrazinamide and Ethambutol. &
12. The method or preparation of claim 11 wherein the anti-TB . formulation is prepared to be adapted for pulmonary administration.
13. The method or the preparation of claim 9 wherein the anti-infective agent comprise at least one of the ingredients selected from the group consisting of Acrosoxacin, Acyclovir, Amantadine, Amicacin, Amifloxacin, Amikacin, Aminosalicyclic Acid, Amoxicillin, Amphotericin B, Ampicillin, Apalcillin, Azidamphenicol, Azithromycin, Azlocillin, Aztreonam, Bacampicillin, Bacitracin, Bacitracin Zing, Benzoic Acid and Salicyclic Acid, Benzyl penicillin (Penicillin G), Butoconazole, Capreomycin, Carbenicillin, Carfecillin, Carindacillin, Cefaclor, Cefadroxil, Cefalexin, Cefamycins, Cefdinir, Cefepime, Cefetamet Pivoxil, Cefixime, Cefmenoxime, Cefodizime, Cefonicid, Cefoperazone, Ceforanide, Cefotaxime, Cefotetan, Cefotiam, Cefoxitin, Cefpiramide, Cefprozil, Cefsulodin, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Cefuroxim, Cefuroxime Axetil, Cephaloridine, Cephamandole, Cephazolin/Cephradine, Cephradine, Cetatriazine, Chloramphenicol, Chloramphenicol, Chlortetracycline, Ciclopirox, Ciclopirox Olamine, Cinoxacin, Cipofloxacin, Ciprofloxacin, Clarithromycin, Clavulanic Acid, Clindamycin, Clofazimine; Clotrimazole, Cloxacillin, Colistin (Colisten Sulfate), Co- Trimoxazole (Trimethoprim + Sulphamethoxazole), Cycloserine, Dapsone, Demeclocycline, Dicloxacillin, Didanosine, Doxycycline, Econazole, Enoxacin, Enrofloxacin, Erythromycin, Ethambutol, Ethionamide; Famciclovir, Fleroxacin, Flucloxacillin, Fluconazole, Flucytosine, Fluxonazole, Foscarnet, Ganciclovir, Gentamicin, Gentamicin Sulfate, Glycylcylines, Griseofulvin, Haloprogin, Hetacillin, Idoxuridine, Imidazoles, Imipenem, Interferons Alfa, Intrathecal, Iodide, Isoniazid, Itraconazole, Kanamycin, Ketoconazole, Lamivudine, Latamoxef (Oxacephalosporin), Levofloxacin, Lomefloxacin, Loracarbef, Mafenide Acetate, Menazopyridine, Meropenem, Metaampicillin, Methacycline, Methenamin, Methicillin, Mezlocilin, Miconazole, Miningeal, Minocycline; Nadifloxacin, Nafcillin, Naftifine, Nalidixic Acid (Oxolinic Acid), Natamycin, Neomycin, Netilmicin, Nitrofurantoin, Norfloxacin, . Nystatin, Ofloxacin, Oxacillin, Oxiconazole, Oxytetracycline, Pefloxacin, Penciclovir, Phenoxymethyl-Penicillin (Penicillin V), 40 Phthalylsulphathiazole, Pipemidic Acid, Piperacillin, Piromidic Acid, ) Pivampicillin, Pivcephalexin, Pivmecillinam, Polymyxin B (Polymyxin B Sulfate), Potassium Iodide, Propionic Acid And Caprylic Acid,
Pyrazinamide, Ramoplanin (Glycopeptide), Riampin, Ribavirin, 3 Rifabutin, Rifampin, Rimantadine, Roxithromycin, Rp 59500, Rufloxacin, Silver Sulphadiazine, Sorivudine, Sparfloxacin, Spectinomycin, Stavudine, Streptomycin, Succinylsulphathiazole, Sulbactam, Sulconazole, Sulfacetamide = Sodium, Sulfadoxine, Sulfametopyrazine, Sulfisoxazole Diolamine, Sulphacetamide, Sulphadiazine, Sulphadimethoxine, Sulphadimidine, Sulphafurazole, Sulphaguanidine, Sulphamethoxazole, Sulphamethoxydiazine, Sulphamethoxypyridazine, Sulphapyridine, Sulphasalazine, Talampicillin, Tazobactam, Teicoplanin (Glycopeptide), Temocillin, Terbinafine, Terconazole, Terconazole, Tetracycline, Tetracycline Hydrochloride, Thiamphenicol, Ticarcillin, Tioconazole, Tobramycin, Tobramycin ~~ Sulfate, + Tolnaftate, Tosufloxacin, Trifluridine, Undecylenate, Undecylenic Acid, Valacyclovir, Vancomycin,
Vidarabine, Vidarabine, Zalcitabine, Zidovudine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200300366A ZA200300366B (en) | 2000-07-19 | 2003-01-14 | Enhancement of the action of anti-infective agents. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200003644 | 2000-07-19 | ||
ZA200300366A ZA200300366B (en) | 2000-07-19 | 2003-01-14 | Enhancement of the action of anti-infective agents. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200300366B true ZA200300366B (en) | 2004-06-29 |
Family
ID=34083725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200300366A ZA200300366B (en) | 2000-07-19 | 2003-01-14 | Enhancement of the action of anti-infective agents. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200300366B (en) |
-
2003
- 2003-01-14 ZA ZA200300366A patent/ZA200300366B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5314904A (en) | Pharmaceutical compositions containing rifaximin for treatment of vaginal infections | |
CA2416512C (en) | Enhancement of the action of anti-infective agents | |
JP2017014293A (en) | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same | |
JP2002500233A (en) | Anti-cryptococcal peptides | |
JP2021042240A (en) | Treatment of erectile dysfunction and other indications | |
EP0339709A2 (en) | Antifungal compositions and method of controlling mycotic infections | |
EP1385511A1 (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis | |
KR20110010763A (en) | Proguanil to treat skin/mucosal diseases | |
EP1476195B1 (en) | Enhancement of the action of central and peripheral nervous system agents | |
JP5954745B2 (en) | Topical pharmaceutical composition of mupirocin | |
US8937074B2 (en) | Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances | |
ITMI952221A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS FOR VAGINAL USE | |
CN104244942A (en) | Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections | |
Kassab | DEVELOPMENT OF NOVEL ANTIMICROBIAL TETRACYCLINE ANALOG B (IODOCYCLINE) BY CHEMO-INFORMATICS. | |
ZA200300366B (en) | Enhancement of the action of anti-infective agents. | |
US20180289656A1 (en) | Compositions and methods to treat urinary tract infections | |
US20200237705A1 (en) | Method to treat antimicrobial resistant candida | |
WO2002098463A1 (en) | Antifungal compositions | |
AU2013254849B2 (en) | Treatment method for steroid responsive dermatoses | |
CN103127136A (en) | Skin drug composition containing methylprednisolone aceponate and amino acid | |
Kassab | DEVELOPMENT OF NOVEL ANTIMICROBIAL TETRACYCLINE ANALOG B (IODOCYCLINE) BY CHEMO-INFORMATICS. | |
JPH0466538A (en) | Antiulcer agent | |
US3772438A (en) | Antibiotic compositions containing coumermycin | |
WO2020116570A1 (en) | External preparation for skin | |
JPS58210011A (en) | Antitumor agent |